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1.1 INFLAMMATORY BOWEL DISEASE (IBD) 
IBD consists of Crohn’s disease, ulcerative colitis and inflammatory bowel disease, type 
unclassified. This group of diseases is characterised by chronic, relapsing and remitting 
inflammation of the gastrointestinal tract associated, in some instances, with extra-intestinal 
signs and symptoms, and distinguished by the location and depth of inflammation.  
 
IBD is a diagnosis that is made when results of endoscopic, histological, serological and 
radiological tests confirm gastrointestinal tract inflammation in a symptomatic patient. No 
one test is diagnostic and a combination of some or all of the aforementioned is contributory. 
It is imperative that an alternative cause for inflammation, such as infection, ischaemia or 




IBD is a life-long condition which affects people at any age from infancy to old age. At the 
present time, no cure for IBD exists and its exact cause remains elusive. Current 
understanding holds that IBD occurs in a genetically-predisposed host when immune 




Recent evidence points to an increased incidence of IBD particularly in childhood, early and 
middle adulthood.
2
 This reality underscores the importance of IBD research: only when the 




1.1.1 CROHN’S DISEASE (CD) 
CD can affect any length of the gastrointestinal tract between the mouth and anus. Lesions 
can be non-contiguous or patchy; inflammation is typically transmural and often includes 
granulomas.
1, 6
 Clinically, CD manifests chiefly as gastrointestinal symptoms such as 
diarrhoea (with or without per rectal blood), abdominal pain and malnutrition.  Extra-






1.1.2 ULCERATIVE COLITIS (UC) 
Inflammation in UC is confined to the large bowel or colon. Lesions typically extend 
proximally, in a contiguous fashion, from the rectum.
6
 In contrast to CD, UC is characterised 
by more superficial inflammation involving just the mucosa.
6
 Like CD, the clinical 
presentation of UC is notable for the predominance of gastrointestinal symptoms which can 
sometimes also be associated with extra-intestinal involvement. 
 
1.1.3 INFLAMMATORY BOWEL DISEASE , TYPE  UNCLASSIFIED (IBDU) 
The diagnosis of IBDU is reserved for cases in which colonic inflammation exists (without 
concurrent small bowel involvement) but distinction between CD and UC is not able to be 
made on endoscopic or histological grounds.  
 
1.1.4 CLASSIFICATION OF IBD 
The heterogeneity of IBD
2, 8
 prompted a number of classification systems to be devised, and 
subsequently revised, over the last two decades.
8
 These systems, all named for world cities, 
have been refined to enable the clinician to classify IBD based on age of diagnosis, disease 
phenotype, disease extent and disease location.  
The Rome classification published in 1991 suggested a classification system based on 




In 1998, the World Congress of Gastroenterology presented the Vienna classification
8
 of 
Crohn’s disease: it considered age of onset (A), disease location (L) and disease behaviour 
(B) as the primary phenotypic distinguishers. This proved a tool which had greater research 
than clinical appeal.
8
 Its main limitation was felt to be that, according to the Vienna 
classification, disease location characterisation had to be mutually exclusive. 
Following a further seven year interval, a Working Party presented the Montreal 
classification at the 2005 World Congress of Gastroenterology. This system incorporated a 
separate category for diagnoses of CD made aged 16 years or younger, as well as an 
4 
 









Where the Rome and Vienna systems did not include a separate classification index for UC, 
the Montreal classification did based on the extent of colonic disease. This classification 
system for UC was justified on the basis that it had relevance to patient response to therapy as 




To account for disease progression (or regression) over time in cases of CD, the Montreal 
consensus statement allowed for a stipulated time to be set in studies before disease 
behaviour is characterised.
8
 In UC, the classification proposed that the maximal extent of 
disease involvement be the critical parameter.
8
 The Working Party also suggested a scale to 
classify severity of relapse with the Montreal system. 
The Montreal Working Party further recommended that the term IBDU replace 
“indeterminate colitis” – a diagnosis they recommended be used in instances where 








Table 1.3: The Montreal classification of UC severity (reproduced from 
8
) 
In 2011, a modification to the Montreal classification was developed which was felt to be 
more appropriate for describing aspects especially pertinent to paediatric IBD. The Paris 
classification included some important modifications
9
 to all three classification categories for 
CD suggested by the Montreal system. Specifically, age at diagnosis was further sub-
classified to 0-10 years (A1a) and 10 to <17 years (A1b). Upper gastrointestinal disease was 
also dichotomised to gastro-oesophageal or duodenal (L4a) and jejunal/proximal ileal disease 
(L4b) with the ligament of Trietz to serve as the anatomical divide. The Paris group 
suggested that the increased incidence of stricturing and fistulising CD occurring 
independently of each other in children, compared to adult evidence which suggested that the 
latter was a consequence of the former, warranted an additional behaviour category (B2B3)  - 
for instances when they co-existed.   
With regards to UC, the Paris classification suggested an additional sub-category to denote 
disease extent proximal to the hepatic flexure (E4) as well as a simplification of the severity 
categorisation to either ever (S0) or never (S1) severe disease – the former applying to UC 
patients who have had severe disease (defined by a Paediatric Ulcerative Colitis Activity 
Index
10
 score of ≥ 65) on at least one occasion.  
6 
 
In recognition of the impact on growth that IBD can have in children, the Paris group 
suggested a separate phenotypic category be added. They recommended G0 for patients who 
have never had growth impairment and G1 for patients who met specified criteria for impaired 
linear growth.  
 





Table 1.5: The categorisation of growth status in paediatric IBD based on the Paris 











As this thesis will focus on the epidemiology of paediatric IBD, the Paris classification will 
be used in all instances unless otherwise stated. 
8 
 
1.1.5 OVERVIEW OF FACTORS ASSOCIATED WITH THE PATHOGENESIS OF IBD 
IBD has been described as a “non-Mendelian polygenic disorder with important 
environmental modifications.”
11, 12
 To explore all that is known on this topic is beyond the 
scope of this chapter. Rather, what follows is a summary of the pertinent genetic and 
environmental factors associated with IBD. Genome-wide association scans have identified at 
least 163 genetic risk loci which are associated with IBD.
13-15
 Most of these provide 
overlapping risk for both CD and UC.
13, 14, 16
 In general, the genes involved in paediatric-
onset IBD do not differ from those associated with adult-onset disease - implying the 
important role of environmental modifiers as triggers of IBD in genetically-susceptible 
children. 
Genes involved in the pathogenesis of IBD are understood to cause dysfunction of the 
gastrointestinal immune system and barrier function and may indirectly involve communities 
of the intestinal microbiome.
13
 The role of genetics in IBD is illustrated by concordance rates 
in monozygotic twins of 10-20% and 30-50% for UC and CD respectively,
4, 13
 higher than 
those for dizygotic twins. There is also an increased risk of developing IBD in individuals 
who have a family member affected by the disease,
17
 a factor especially pertinent in early-
onset IBD.
3, 18-20
 Some have suggested that genetic anticipation may account for the early-
onset of IBD in children who have a family history of the disease.
20-22
 
The greatest risk factor for developing IBD is having a first-degree relative with IBD.
11, 17
 
Offspring of parents with CD are more likely to develop IBD (0 - 15.8%) than are offspring 
of parents with UC (2.9 – 11%) – this effect is more pronounced in people of Jewish 
heritage.
11




Twin studies have shown that genetics has an impact on the disease characteristics of twins 
with CD, and to a lesser extent those with UC.
4
 Monozygotic twins with CD have been 
shown to be concordant for age of onset of IBD symptoms, extent of inflammation, disease 
severity and disease behaviour.
4
 Monozygotic twins with UC meanwhile were shown to be 
concordant for extent of disease and need for thiopurine drugs.
4, 20
   
In families with CD, concordance for disease phenotype has been described with certain 
genes associated with specific phenotypes of CD.
4
 As an example, the nucleotide 
oligomerisation domain (NOD)2/CARD 15 genotypes are associated with younger age of 
9 
 
disease onset, ileal and stricturing disease
21, 23-25
 and disease in Western populations
17
 
whereas polymorphisms of the OCTN 1 and 2 genes within the IBD5 locus are associated 
with perianal disease.
26
 IL27 has been identified separately as a candidate gene for Crohn’s 
disease susceptibility, complementing gene discoveries in other genome scans (Il23R, 
STAT3, JAK2 and ILI2b).
18
 Furthermore, a variant of the CXCL9 gene is associated with 
paediatric Crohn’s disease.
3
 Indeed, the CXCR3 axis (of which CXCL9 forms one of three 
ligands) is demonstrably over-expressed in patients with active IBD.
3
 
The increasing incidence of IBD across geographical and ethnic boundaries cannot solely be 
explained by genetics.
22
 The rate of increase over a relatively short period of time means the 
possibility of a significant change to the genetic pool in different population groups is slim.
17, 
27, 28
 Also, twin studies have suggested that inherited genetic risk plays only a small role in 
IBD pathogenesis.
28
 More to the point, however, is the noted increase in incidence of IBD in 
countries in which “development” has led to a “Westernisation” of the population life-style.
13, 
14
 Especially interesting is the high incidence amongst certain immigrant populations who 
emigrate from low to high incidence areas;
13, 21, 29-31
 a virtual case-controlled study in which 
the exact environmental factors in the new place of residence, which presumably account for 
the increased IBD incidence, remain unknown. Also worth exploring (and an area of much 
research) is the potential environmental factors in childhood which would account for the 
onset of IBD early in life. 
A significant association has been demonstrated between CD and maternal smoking in 
pregnancy and maternal age of greater than 35 years at delivery.
13
 Evidence linking lower 
segment Caesarean sections (LSCS) and IBD is conflicted.
13
 A recent systematic review and 
meta analysis found no significant difference in the rates of IBD between children born 
vaginally compared with those delivered by LSCS.
32
 The proposed theory which might 
support an association (if one exists) between mode of delivery and IBD is the differing 
intestinal microbiome in children born vaginally compared with those born via LSCS.
19
 
Similarly, it is not clear if higher birth order i.e. being born earlier than any sibling(s) and 
smaller families increase the risk of IBD.
13, 33
 Caucasian children however, have been shown 
to have an increased risk of developing IBD compared to children of other races.
19
 While the 
quality of existing research on the topic is admittedly poor, consensus from the literature 





The hygiene hypothesis, first described in 1989,
36
 proposes a theory which might account for 
the increased incidence of IBD worldwide.
21
 It suggests that decreased exposure to micro-
organisms in childhood, a result of improved hygiene and living standards, is largely 
accountable for the rise in chronic auto-immune and atopic conditions. In support of this 
theory are a number of studies which show reduced seroprevalence of Helicobacter pylori (H. 
Pylori) , a common gastric pathogen, in patients with IBD.
33
 Other studies have suggested a 
protective role for H. Pylori in both the development and natural history of IBD.
33
 In a 
similar vein, improved hygiene has meant reduced rates of helminthic infections in infancy, 
and thus deprivation of the immunoregulatory role helminths play within the gastrointestinal 
flora.
33
 The cold chain hypothesis meanwhile proposes that the advent of refrigeration has led 
to an increase in IBD. The mechanism by which this might occur is through exposure to 
bacteria which survive or develop at low temperatures.
33
  
The role of the intestinal microbiome in the pathogenesis of CD is becoming increasingly 
recognised.
14, 33
 Patients with IBD display reduced diversity of intestinal micro-organisms 
compared to healthy controls even at diagnosis i.e. prior to the institution of any treatment.
14
 
This dysequilibrium is manifest by reduced subpopulations of potentially-protective bacteria 
and a corresponding increase in potentially-pathogenic ones.
14
 Antibiotics can affect the 
ecology of gut commensals and its role in the pathogenesis of IBD has been investigated. 
Some have highlighted the fact that the increased incidence of IBD in the second half of last 
century closely followed the widespread introduction of antibiotics in the mid-1940s.
33
 A 
nested case-control study comparing subjects with IBD against non-IBD controls found a 
significantly greater number of cases had had at least one episode of otitis media in early 
childhood compared with controls.
37
 In this study, otitis media was used as a proxy of 
antibiotic exposure. More recently, a large retrospective cohort study involving more than 
one million children and adolescents, found that early antibiotic use was associated with an 
increased risk of subsequent IBD development with a cumulative effect reflecting total 
antibiotic exposure also noted.
38
 These and other studies confirm the association between 
antibiotic exposure and IBD development with intestinal micro-organism dysbiosis thought to 
be the most likely causal mechanism.
13
 With regards to childhood immunisations however, 
the weight of evidence suggests no positive association with IBD, in spite of the former’s 





Diet has been shown as another determinant of gastrointestinal tract microbial composition.
13, 
14
 In a controlled environment, modifications to diet resulted in alterations to the intestinal 
microbiome.
14
 This would support the hypothesis that diet may have a role in triggering 
disease relapse. Furthermore, evidence suggests a positive association between high intake of 
protein, polyunsaturated fats, carbohydrate and refined sugars and the development of IBD.
13, 
14
 Meanwhile a high intake of fibre has been shown to reduce the risk of subsequent CD in a 
number of studies.
14
 However the quality of studies investigating an association between diet 
and IBD suffers from inadequate control for confounders, recall bias and differing techniques 




Some evidence points to a higher incidence of IBD in subjects who are vitamin D deficient.
14
 
Furthermore, vitamin D deficiency is also demonstrably associated with increased 
complications from IBD including higher rates of hospitalisation and surgery.
14
 
Epidemiological data suggest that the highest rates of IBD occur in northern lattitudes,
21, 39, 40
 
further advancing the theory that the reduced sunlight exposure in these geographical areas 
may account for greater vitamin D deficiency and therefore higher rates of IBD.
13, 14
 While 
tempting to draw a causal link between the two, some have hypothesised that as much of the 
research in this field has been observational and retrospective in design, vitamin D deficiency 




Tobacco smoking is a well-recognised risk factor for IBD development in children and 
adults, and for severe clinical course in adults.
13, 21
 Current smoking doubles the risk of CD 
development whilst paradoxically halving the risk of UC development (compared to people 
who have never smoked).
14
 It must be added however that smoking cessation is associated 
with a significant increase in the risk of developing UC – an effect which can last up to 10 
years following cessation of the habit.
14
 The impact of tobacco smoking as a risk factor is 
multiplied in those with a family history of  IBD.
13
 Similar to smoking, previous 
appendicectomy is associated with an increased risk of CD but a reduced risk of UC.
33
 The 




Some evidence suggests a positive association between urban living and IBD.
13, 14, 33
 Again, 
the exact mechanism that explains this association is unclear although reduced levels of air 
12 
 
pollution in rural environments is offered as one possibility.
13
 Another possibile explanation 
is the greater exposure to animals that those who live rurally, in general, enjoy compared to 




Other modifiers of IBD risk include medications such as non-steroidal anti-inflammatory 
drugs, oral contraceptives and hormorne replacement therapy as well as certain enteric 
infections.
14, 22
 Psychological stress has also been shown to have a possible association with 
IBD although whether this reflects a causal link or is merely an indicator of disease severity 
remains unclear.
14


















Table 1.7: Summary of evidence of environmental risk factors for IBD development with 
focus on paediatric exposures and disease (adapted from 
13
) 
Environmental factor Disease Strength of association* Number of studies 
(level of evidence**) 
Disease during pregnancy 
 
 
Maternal smoking during 
pregnancy 
 
Maternal age >35 years 
 
Maternal age <20 years 
 























Availability warm water, 










Smaller family size 
 




Birth order ≥ 3 
 
Number of younger siblings 
 
Number of older siblings 
 
Urban household (systematic 
review) 
UC – risk 
n/a 
 
CD – risk 
 
 




CD – protective 
 
 
IBD – protective 
IBD – risk 







CD/UC – risk 
 
IBD – protective 
CD/UC – protective 
 





UC – risk 
IBD/CD - risk 
CD - protective 
 
CD – protective 
 
CD – protective 
 
IBD - risk 
 




IBD – protective 
 

























































































































Air pollution – SO2  
 















































Childhood enteric infections 
 





Overall cohort – n/a 
CD ≤ 23 years - risk 
CD 44-57 years – 
protective 
Overall cohort – n/a 







Number of life events – 
n/a 
CD depression score – 
risk (vs self-limited 
colitis) 
CD anxiety score – risk 
(vs blood donor 
controls) 
UC depression score – 
risk (vs self-limited 
colitis and blood donor 
controls) 
UC anxiety score – 
protective (vs self-
limited colitis) 
Parents divorced: IBD – 
risk 
Death in family: n/a 
Moving countries: n/a 
IBD – risk 
 
 






CD < 5 years – n/a 
CD 5-10 years – risk 
IBD/CD/UC – risk 
 
 
IBD/CD/UC – risk 
CD/UC – risk 
CD/UC – risk 
 
 
IBD/CD/UC – risk 
 
 






































No meta-analysis; diet 
high in animal fat may 
predispose to IBD 
No meta-analysis; diet 
high in total fats, PUFAs, 
omega-6 fatty acids and 
meats may predispose to 





















































































Antibiotic use in first year of 
life 
 
Antibiotic use 2-5 years prior 
to diagnosis 
 
Antibiotic use 6-24 months 








































<5 years: IBD/CD/UC – 
risk 
IBD/CD – risk 
UC – n/a 
 
IBD/CD/UC – risk 
 
 
CD 24 months prior – 
risk 
CD 7-24 months prior – 
risk 
CD 7-12 months prior – 
risk 
CD 6 months prior – risk 
UC 24 months prior – 
n/a 
UC 7-24 months prior – 
n/a 
UC 7-12 months prior – 
n/a 
UC 6 months prior – n/a 
IBD at least 1 course – 
risk 
IBD use in last 3 months 
– risk 
IBD use >3 months ago 
– n/a 
CD at least 1 course – 
risk 
CD use in last 3 months 
– risk 
CD use >3 months ago – 
n/a 
UC at least 1 course – 
n/a 
UC use in last 3 months 
– n/a 
UC use >3months ago – 
n/a 




UC – protective 
IBD/CD/UC – risk 
UC – protective 
CD – risk 










































Year 1 -4: Moderate 















































One review (CD -
risk) has troublesome 
heterogeneity; the 
other is level 2a 
 
3 (3b and 2b) 
n/a – not applicable; IBD – inflammatory bowel disease; CD – Crohn’s disease; UC – ulcerative colitis; NO2 - nitrogen dioxide; SO2 – 
sulphur dioxide; PM10 – particulate matter 10 micrometres or less; PUFA – polyunsaturated fatty acids 
*Strength of association based on rate ratios (OR, RR, IRR). Weak association, rate ratio 0.9-1.1; moderate association, rate ratio 0.5-0.9 
or 1.1-2.0; strong association, rate ratio <0.5 or ≥2.0 
**Levels of evidence based on Oxford Centre for Evidence-Based Medicine – Levels of Evidence (March 2009) for studies of 
therapy/prevention/etiology/harm: http://www.cebm.net/index.aspx?o=1025 




1.2 DIFFERENCES BETWEEN ADULT AND PAEDIATRIC IBD 
One in four cases of IBD is diagnosed in childhood.
2, 6, 27
 With regards to disease phenotype 
and epidemiology, important differences exist between children and adults who are diagnosed 
with IBD.
2
 Whether these differences are a reflection of different genetics, gastrointestinal 




Among adult IBD patients, there is an equal proportion of males and females affected, or else 
a slight female preponderance in some cases.
6, 43
 This is in contrast to pre-pubertal CD which 
appears to afflict more boys than girls.
21, 43-46
  By some reports, the male to female ratio of 
paediatric CD is as high as 1.5:1.
6, 43
 Similarly, most studies on the topic suggest a male 
predominance of very early onset (age <5 – 8 years) IBD.
43
 The change in distribution at this 
age range has led some to speculate that hormones may be implicated.
2, 46
  The proportion of 
UC is evenly split between the genders among children
21
 whereas adult and elderly-onset UC 
demonstrate a male preponderance.
2, 43
 Within IBD, there is a greater ratio of CD to UC 
diagnoses amongst paediatric patients compared with adult ones where the reverse, albeit to a 
lesser degree, is true.
2, 43
 Some  have demonstrated a CD to UC ratio of 2.8-3:1 in children 
compared to 0.85-1:1 in adults.
6, 43
 The third entity within the IBD umbrella, IBDU, can 
account for between 10 and 15% of paediatric cohorts.
5
 
There is also a documented difference in areas of the gastrointestinal tract affected by IBD 
between adult and paediatric populations.
46
 The majority of children with CD have ileo-
colonic or colonic disease whereas adults with CD are more likely to present with terminal 
ileal disease.
7, 21, 43, 45
 Up to 90% of children with CD have colonic disease compared with 
only half of adult CD patients who experience colonic involvement.
43
 Paediatric CD patients 
are also more likely to have disease progression i.e. greater degree of gastrointestinal tract 
involvement at follow-up compared with their adult counterparts.
7, 43
 Upper gastrointestinal 
tract and perianal disease is more common in paediatric-onset CD compared with adult-onset 
CD.
7
 In UC cases, paediatric patients are more likely to present with more extensive pan-
colonic involvement
5, 45




Paediatric patients with CD are more likely to present with inflammatory disease compared 
with adults who more often present with stricturing and penetrating disease.
7, 20, 43
 It is worth 
noting, however, that a significant proportion of children with CD progress from 
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inflammatory to stricturing disease in time.
43
 With respect to UC, paediatric patients not only 
present with more extensive colonic involvement compared to adults but also a more 
aggressive phenotypc of disease.
43
 At ten-years following diagnosis, 40% of children with 
UC had undergone colectomy compared to half that percentage in adult UC patients.
43
 
While differences clearly abound, paediatric and adult IBD do share some aspects in 
common. Most of the known genetic risk factors for IBD are true for both childhood and 
adult-onset diease.
43
 Similarly, clinical presentation of IBD appears to be disease-location, 
rather than age, dependent.
43
 Even the rate of extra-intestinal manifestations are comparable 
among paediatric and adult cohorts.
7, 43
 That said,  effect on growth is a clinical feature 
unique to paediatric IBD patients.
6, 28, 43
 Poor growth leading up to diagnosis has been shown 
in multiple studies.
20, 43
 The reasons for growth impairment in children with IBD include 
malnutrition, uncontrolled inflammation and treatement with corticosteroids.
7, 20
 More 
worryingly, some research has shown that catch-up growth does not always occur.
43
 Other 
evidence points to the effect of delayed puberty in children with IBD and reduced adult 
height consequent to this.
43
 
The differences between paediatric and adult IBD cannot be easily explained. Intuition would 
suggest that genetics play a greater role in  disease manifestation among paediatric patients 
whereas environmental modifiers have a similar effect in adult-onset disease. Paediatric IBD 
patients generally have less co-morbidities than their adult couterparts and therefore serve as 
purer models of its natural history. Also in cases of paediatric IBD, parents may be able to 
assist in genetic studies which could prove invaluable. The theory that increasing paediatric 
IBD is a reflection, not of a true rise in disease burden, but rather a shift to an earlier age of 
diagnosis has been debunked.
5, 22, 28, 45, 47, 48
 With this in mind, research focussed on paediatric 
IBD could prove vital in unravelling the interplay between genetic susceptibility and 
environmental risk in the manifestation of this chronic disease with significant associated 
health-care costs.
49
 Epidemiological research contrasting rates and trends in developed and 
developing countries (as the latter adopt a more “westernised” lifestyle) as well as studies 








1.3 DESCRIPTIVE EPIDEMIOLOGY 
Descriptive epidemiology is the science of describing disease distribution by person, place 
and time.
50
 The goal of epidemiological research is to provide evidence that eventually leads 
to prevention or reduction in the occurrence of any given disease. The results of descriptive 
epidemiology are reported in a series of measures. Counts are the most basic descriptor – the 
number of events being studied.
50
 Counts offer limited use without the context (or 
population) within which they occur. Proportions describe the percentage of a population 
affected by, or exposed to, the disease being studied.
50
 Ratios are a comparator between two 
proportions; for example the ratio of men to women in a study.
50
 Rates describe the 
proportion of disease per specfied period of time.
50
 Incidence and prevalence are two 
examples of rates measurements. 
Point prevalence is a proportion, obtained by dividing the number of people affected by the 
disease in question at a specified point in time, over the total number of people in that 
population group.
50
 Period prevalence by contrast refers to the proportion of people affected 
by the disease over a period of time with the mean population size over that same period 
serving as the denominator.
50
 The other important measure of disease frequency is its 
incidence. The incidence of a disease is the number of new cases occuring within a 
population group.
50
 Cumulative incidence is defined by the number of new diagnoses of a 
particular disease which occur over a specified period as a proportion of the non-diseased 
cohort within that population group.
50
 Incidence density on the other hand is the number of 
new diagnoses over a specified time period divided by the total person-time of observation.
50
 
One individual followed for four years during a study would contribute four person-years of 
observation. 
Prevalence is a useful measure when it comes to the allocation of health-care resources. It 
depicts the burden of a particular disease within a defined population at a point in time. It 
may be able to suggest an aetiologic association but is vulnerable to multiple confounders i.e. 
factors which might explain (away) the apparent link. Incidence, therefore, is the preferred 
measure to study potential causal associations; confounders which might affect survival are 
eliminated and factors which may predict the development of new disease become apparent. 
In this thesis, the point prevalence of paediatric IBD in New Zealand will be researched and 
described. Also the cumulative incidence of new paediatric IBD diagnoses made in 2015 as 
well as the incidence density of paediatric IBD in Canterbury over a 20-year period (1996-
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2015) will be defined. Demographic details and disease phenotypic data will be presented and 
major differences with other paediatric epidemiological studies demonstrated. Potential 
aetiological associations with paediatric IBD will be drawn, where scientifically possible. 
 
1.3.1 DESCRIPTIVE EPIDEMIOLOGY OF PAEDIATRIC IBD 
The incidence of paediatric IBD is increasing throughout the world.
5, 27
 Benchimol et al., in a 
seminal systematic review published in 2011,
28
  reported a significant increase in the 
incidence of paediatric-onset CD globally with stable incidence of paediatric-onset UC in 
most places.  One of the main difficulties encountered by the authors in performing their 
systematic review was the heterogeneity of published data pertaining to paediatric IBD.  
Some studies were hospital-based whereas others used surveys and administrative data. In 
some instances, national rates were inferred from regional rates within that country. Much of 
the published literature was retrospective in design and therefore, particularly in light of 
current diagnostic criteria, subject to misclassification bias. They also found a wide variation 
in the quality of statistical analyses performed, thereby limiting the validity of much of the 
data. Bemoaning the lack of quality that many of the epidemiologic studies relating to 
paediatric IBD possessed, future researchers were encouraged to produce work that was more 
methodically rigorous. 
Since then a number of population-based epidemiological studies have been published, 
mostly out of Europe.
15, 40, 44, 47, 51-53
 In general, these have attested to an increasing incidence 
of paediatric IBD. Locally, a landmark study conducted in 2004 suggested that Canterbury, 
New Zealand had one of the highest rates of IBD (and especially CD) in the world.
54
 In 2008, 
a prospective survey of paediatric IBD in New Zealand reported numbers which were 
“…comparable but at the lower end…” relative to epidemiological studies in other Western 
regions.
55
 The current research hopes to create a prospective nationwide database of 
paediatric IBD with the hypothesis that paediatric IBD rates in New Zealand are among the 
highest reported in the literature. 
In the following sub-chapters a comprehensive (but not exhaustive) review of paediatric 
epidemiological studies is conducted. A MEDLINE search was performed and all studies 
published in English and where the full-text was available online (using institutional login) 
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were selected for review. Studies which had exclusively paediatric data were included 
whereas studies which had paediatric data nested within adult-data were not.  
 
1.3.2 DESCRIPTIVE EPIDEMIOLOGY OF PAEDIATRIC IBD IN EUROPE 
Scandinavia, and the British Isles have provided much of the epidemiological information 
available on paediatric IBD. Allowing for some differences in the quality of reported data, 
many of these publications arose either from centralised health systems whereby one or only 
a handful of centres provided specialised, tertiary-level care (as required by children with 
IBD) or,  systems in which different groups within a sub-specialty of medicine maintained 
close links through specialist associations at national or regional level.  
Through a prospective survey run via the British Paediatric Surveillance Unit (BPSU), a 
validated means by which to monitor disease incidence,
56
 the epidemiology of paediatric IBD 
was documented at the end of the last century in a population-based fashion across the British 
Isles.
57
 The authors found that the incidence of paediatric IBD across the United Kingdom 
(UK) and Republic of Ireland was 5.2/100 000 children per year. When broken down by 
country, Scotland was found to have the highest incidence of paediatric IBD at 6.5/100 000 
children per year with a CD incidence of 4.2/100 000 children per year. The Scottish 
incidence of paediatric IBD was an increase from 4.5/100 000 children per year documented 
in a study done in 1983.
58
 In 2012, a retrospective and prospective, population-based study
44
 
concluded that the incidence of paediatric IBD in under 16 year olds in Scotland had 
increased by 76% to 7.82/100 000 children per year between 2003 and 2008 (following age 
and sex-standardisation) compared to an incidence of 4.45/100 000 children per year between 
1990-1995. The authors concluded that the incidence of paediatric IBD (and CD and UC, 
individuallly) continued to rise in Scotland. 
These findings are mirrored in other parts of the UK. In a population-based study centred 
around Wessex in the South of England,
59
 the incidence of paediatric IBD was reported to be 
9.37/100 000 children (under 16 years) per year between 2008 and 2012 compared to 
6.39/100 000 children per year between 2002 and 2006, a statistically-significant increase. 
The incidence of CD and UC in the most recent cohort in that study was 5.85 and 2.01/100 
000 children per year, respectively. In Ireland, a retrospective, population-based survey
51
 
conducted in the only paediatric gastroenterology unit in the country (which reported to 
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approximate a national cohort) demonstrated an age-adjusted mean incidence of 3.9/100 000 
children per year between 2000 and 2010. The authors also reported a mean annual increase 
in incidence of CD and UC of 0.153 and 0.175/100 000 children per year, respectively. In the 
Irish survey, comparisons of disease phenotype were made between the earlier and latter 
cohorts and no significant differences were found insofar as disease location or behaviour (in 
cases of CD). A Welsh survey,
56
 run via the Welsh Paediatric Surveillance Unit, and  which 
boasted remarkably high-response rates, reported incidence rates of 2.6, 1.36, 0.75 and 
0.48/100 000 children per year for paediatric IBD, CD, UC and indeterminate colitis (as they 
reported it), respectively. A population-based, prospective study over eight years conducted 
in South Wales,
60
 suggested that in that locality, incidence of paediatric IBD appeared to have 
reached a plateau; the incidence of paediatric IBD, CD and UC being 5.4, 3.6 and 1.5/100 
000 children per year, respectively. Published in 2006 in the format of a short report, this 
study’s significant weakness was the lack of a thorough description of its results and 
statistical analyses thereof. 
A prospective 12-year study conducted in northern Stockholm,
61
 Sweden reported an IBD 
incidence of 7.4/100 000 children per year, with incidence rates for CD and UC of 4.9 and 
2.2/100 000 children per year, respectively. These high rates were surpassed in a more recent 
retrospective, population-based study
15
 conducted in the same geographical area which 
reported staggeringly high standardised incidence rates of 12.8, 9.2 and 2.8/100 000 children 
per year. The increased incidence rates of paediatric IBD and UC between both study periods 
were of statistical significance.  
A 2006 publication, documented the population-based rates of paediatric IBD in a north-
eastern region of Norway.
62
 Using a similar methodology to some previously referenced 
studies, the authors found a stable incidence of paediatric IBD at 5.65/100 000 children per 
year when they compared two time periods between 1993 and 2004.  This study also 
documented a downward trend for the incidence of UC and an upward trend for the incidence 
of CD over the same time periods – attributable, according to the authors, to improved 
diagnostics. Whilst true that the practice of performing diagnostic upper gastrointestinal 
endoscopy in cases of suspected paediatric IBD is a relatively modern one (as indeed is the 
more routine use of capsule endoscopy and magnetic resonance enterography), these changes 
in diagnostic modalities are unlikely to fully account for the increased incidence of CD.
45
 
This study also demonstrated that pancolitis was the most common presentation of childhood 
UC whereas ileo-colonic involvment was most common among paediatric CD – concluding 
22 
 
that the phenotype of paediatric IBD was more severe than adult-onset disease. A more recent 
population-based study conducted in the same region of Norway
45
 showed a dramatic 
increase in the incidence of paediatric CD (with a stable UC incidence). An inception cohort 
was included in this latter study,
45
 conducted between May 2005 and December 2007, and 
when the numbers were restricted to children under 16 years of age residing in Akershus (the 
same geographical region as the earlier study), the IBD, CD and UC incidence were 10.8, 7.7 
and 2.0 /100 000 children per year, respectively. 
The experience of two tertiary level centres in Southern Finland, which represent more than 
50% of the paediatric population in that country, reported a 1.8 fold increase in the incidence 
of IBD between 1987 and 2003.
63
 In a retrospective chart review of every patient with IBD 
under 18 years of age, the incidence rate was found to be 3.9/100 000 in 1987 compared with 
7.0/100 000 in 2003. Of particular note among this cohort, across all age groups and 
throughout the study period, UC was more prevalent than CD.  
In Iceland, a nationwide, retrospective and prospective epidemiological study which reviewed 
data over six decades (case ascertainment for which was aided by the centralised health 
system available in that country),
53
 there was a rise in the incidence of paediatric IBD from 
1.2 to 5.0/100 000 children per year between the first and last decades of the study period. 
When their results were further broken down, the incidence of IBD appeared to be rising 
steadily up to the last decade during which time it appears to have reached a plateau; the 
incidence of paediatric IBD in the last decade of the 20
th
 century in Iceland being 5.6/100 000 
children per year. A prospective Hungarian study published in 2013,
47
 and conducted in a 
population-based manner with rigorous case ascertainment across the whole country, reported 
incidence rates of 7.48, 4.72, 2.32 and 0.45/100 000 children per year of paediatric IBD, CD, 
UC and IBDU, respectively. These figures however need to be interpreted with caution as the 
inclusion criteria allowed for young people up to their 18
th
 birthday to be included in the 
study analyses – in contrast to most paediatric IBD epidemiological data which set their cut-
offs at 15 or 16 years of age. Among the phenotypic findings of note in this study were the 
10% rate of extra-intestinal manifestations at diagnosis, the 5% rate of needing surgery 
among the CD cohort (albeit with a short follow-up period) and ileo-colonic CD and pan-
colitic UC being the most common areas of involvment, in keeping with the literature.  
Also from Eastern Europe, data from the Czech Republic points to an increasing incidence of 
CD. A single tertiary-centre’s experience
64
 over a 12-year period suggested a statistically-
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significant increase in the incidence of CD. Published in the form of a letter, a single-centre’s 
experience which serviced less than 10% of the national population and which included years 
during which not a single diagnosis of paediatric IBD was made needs to be interpreted with 
much caution and should not be extrapolated to reflect national trends. A more recent Czech 
study published in 2006,
65
 conducted with substantially more rigour and purporting to report 
national rates reported a five-fold increase in the incidence of CD; from 0.25/100 000 
children in 1990 to 1.25/100 000 in 2001. Of interest in this study, the terminal ileum was the 
most commonly affected region – although the study design’s failure to use a universal 
classification system (such as the Montreal one) made comparison with other studies 
difficult.  
A number of Western European countries have also reported national and regional paediatric 
IBD rates. A prospective 12-year study conducted in northern France
66
 reported the mean 
annual incidence of paediatric IBD to be 3.1/100 000 children. When comparing rates 
between the first and last three years of the study period, the rates of CD increased with a 
concomitant decrease in the rates of UC, 5.2 to 6.4 and 4.2 to 3.5/100 000 children per year. 
The main drawback of this study was its inclusion for analyses of “definite” as well as 
“probable” cases of paediatric IBD. Even though clear definitions were given for each 
category, the study’s long follow-up period should have allowed for a definitive diagnosis 
being made. A nationwide, retrospective study conducted in Spain
40
 reported a significant 
increase in the burden of paediatric IBD from an incidence rate of 0.97 to 2.8/100 000 
children per year. This reflected a rise in annual cases of both CD and UC, individually. In a 
prospective, population-based study conducted in the Netherlands,
39
 the national paediatric 
IBD incidence was calculated to be 5.2/100 000 children per year. Both the Spanish and 
Dutch studies included young people under the age of 18 years in their analyses. 
 
1.3.3 DESCRIPTIVE EPIDEMIOLOGY OF PAEDIATRIC IBD IN NORTH AMERICA 
In an ambitious 2009 publication,
67
 Benchimol et al. sought not only to define the IBD 
burden in Ontario, Canada but also to define the ideal algorithm for accurate case 
ascertainment in aid of future IBD research conducted in similarly set-up health provision 
systems. After a rigorous validation process, the selected algorithm consisted of a different 
number of physician contacts and/or hospitalisations over a three-year period depending on 
whether a child had had endoscopy or not. In their retrospective, population-based review 
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which included young people under the age of 18 years between 1991 and 2008, and using 
health administrative data from multiple sources, the incidence of IBD in that locality 
increased from 9.5 to 11.4 /100 000 children per year. Although the CD incidence showed a 
non-significant upward trend, the incidence of UC remained stable throughout the study 
period. 
Also in 2009, a study conducted in Southwestern Ontario was published detailing the 
incidence of paediatric IBD in that population.
68
 Looking back over a ten-year period, the 
authors compared the incidence of IBD in those up to the age of 17 years between 1997 and 
2001 with that between 2002 and 2006. While the overall incidence of IBD between the latter 
and former periods decreased from 14.3 to 12.4 /100 000 children per year, the incidence of 
CD increased significantly from 3.5 to 6.01 /100 000 children per year whereas the incidence 
of UC showed a significant decline from 10.6 to 6.01 /100 000 children per year. 
Interestingly in this study, the surgical rate among paediatric patients with IBD showed a 
non-statistically significant decline from 43% to 31% between the earlier and later cohorts. 
The authors postulated that increasing use of biologic agents might account for this 
downward trend and rather than necessarily reduce, it may in fact delay the need for surgery.  
In British Columbia, the impact of emigration and environmental modifiers on the incidence 
and phenotype of IBD was studied. By conducting a retrospective chart review of all patients 
seen in the only paediatric gastroenterology centre serving the area, population-approximate 
incidence rates were calculated for  South Asian and non-South Asian residents of British 
Columbia under the age of 16 years between 1996 and 2001.
30
 This revealed that the average 
annual incidence of paediatric IBD among the South Asian population was significantly 
higher compared to that of the non-South Asian population – 15.19/100 000 children per year 
compared to 5.19/100 000 children per year. This reported incidence rate among the South 
Asian paediatric population of British Columbia is one of the highest rates documented in the 
literature.
30
 Other findings from this study included more extensive colonic disease and a 
shorter duration of symptoms leading to diagnosis among South Asian children with IBD. 
The most significant population-based data to emerge from the United States pertaining to 
paediatric IBD has come out of Wisconsin. In a pilot study published in 2003, Kugathasan et 
al.
69
 reported a statewide incidence of IBD, CD and UC of 7.05, 4.56 and 2.14 /100 000 
children/ year among under 18 year olds. Their prospective study involved voluntary-
reporting on a survey which went to significant lengths (including surveying physicians in a 
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neighbouring state) to avoid missing new diagnoses. This notwithstanding, the likelihood is 
that particularly among the older teenage population, new diagnoses made by adult 
gastroenterologists would have been missed. Of interest in this study, the authors found no 
effect of urbanisation, nor disparity along ethnic lines, on the rates of paediatric IBD.  In a 
follow-up study by the same group, an eight-year population-based prospective review also 
conducted in the state of Wisconsin found a relatively stable, but high, incidence of IBD – 
9.5/100 000 children per year with the incidence of CD, UC and IC (as defined by the 
authors) being 6.6, 2.4 and 0.5 /100 000 children per year, respectively. The authors 
suggested that the relatively static incidence might be a direct reflection of Wisconsin’s stable 
population make-up which had had minimal impact from immigration. 
The annual incidence of paediatric IBD in Northern California was reported to be, on 
average, 2.7, 3.2 and 0.5 /100 000 children per year for CD, UC and IC (as the authors 
defined it) respectively. This retrospective chart review was conducted over an 11-year span 
between 1996 and 2006 of the database of one of the area’s biggest health insurance 
providers.
31
 Their data revealed a significant increase in the incidence of UC from 1.8 – 4.9 
/100 000 children per year with a similar non-significant increase in the incidence of CD 
from 2.2 to 4.3 /100 000 children per year. Being data derived from a health insurance 
provider (which by its own account only represented about 30% of the area’s population), 
these numbers should not be extrapolated to reflect state-wide trends, for obvious reasons. 
 
1.3.4 DECRIPTIVE EPIDEMIOLOGY OF PAEDIATRIC IBD IN THE MIDDLE EAST 
AND ASIA 
Israel’s population, which consists of a large percentage of immigrants to the country, affords 
a unique opportunity to study the impact of environmental modifiers on disparate genetic 
predispositions.
70
 In a study published in 2013,
70
 the prevalence of IBD among Jewish 
adolescents was described over time by looking through a nationwide database which 
included health details of the vast majority of 17-year olds in the country - garnered from a 
compulsory medical evaluation which serves as a prerequisite to possible military service. 
Conducted retrospectively over a 13-year period, the study reported an increase in the 
prevalence of IBD among Jewish adolescents with a median age of 17 years from 149.4 – 
301/100 000. In attempting to identify socio-demographic factors which may influence the 
development of IBD, the authors found that there was an over-representation of males and 
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people of Western origin, higher socio-economic status as well as those belonging to families 
of greater than four children. Aside from its retrospective design, the study’s drawbacks 
included the fact that collected data included neither the age at IBD diagnosis nor the type of 
IBD. Also, an estimated 13% of female Jewish adolescents were not accounted for in the 
study by virtue of their exemption from military service on religious grounds.  
In the Middle East, a 2006 publication reported low prevalence of IBD in those under 18 
years of age – 5/100 000 in Riyadh in Saudi Arabia.
71
 This retrospective study possessed 
serious methodological flaws however;  a single-centre’s experience was extrapolated to 
represent the experience of the three other paediatric gastroenterology centres in the region 
and population-based conclusions were inferred from this. That notwithstanding, it was 
interesting to note that in this study, more females than males were affected by IBD and that 
UC occurred more commonly than CD. The author’s concluded that whilst low, the incidence 
of juvenile-onset IBD in Saudi Arabia was rising. 
In keeping with this trend, a more recent Kuwaiti publication
72
 reported rates of IBD in 
children aged 15 years and under that were comparable to population-based data from 
Western countries. Reporting a single tertiary-centre’s experience which approximated a 
national cohort (by virtue of being the only paediatric gastroenterology unit in the country), a 
10-year retrospective chart review found an average annual incidence of paediatric IBD of 
2.16/100 000 children per year. Of note in this review, there was a slight female preponderace 
among those affected by paediatric IBD (53%) and a positive family history was found in 
23% of the affected patients, higher than in other reports. In keeping with the litreature 
however, ileocolonic CD and pan-colonic UC were the most common presenting disease 
phenotypes. 
A South Korean retrospective review published in 2009 reported a single centre’s experience 
of paediatric IBD. This study found an increasing trend of paediatric IBD diagnoses. While 
appearing to be mindful of the inherent bias in a single-centre’s experience, the authors 
nevertheless suggested that the rising incidence which they found was reflective of a national 
trend. Also, their methods included using two different classification systems for detailing 
IBD phenotype. While these weaknesses mean that results from this study need to be 
interpreted with caution, they also speak to two prevailing truths in the literature: 1) the 
incidence of paediatric IBD appears to be on the rise across the world, including in areas 
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previously thought to have a low disease burden
28, 73
 and 2) the paucity of good-quality 




1.3.5 DESCRIPTIVE EPIDEMIOLOGY OF (PAEDIATRIC) IBD IN AUSTRALASIA 
Historically, the burden of of IBD in Australasia was thought to be low. This was based on 
hospital or tertiary case series in the absence of population-based figures.
73, 75-77
 In the last 
decade however, evidence has emerged from robust retrospective and prospective studies 
which point towards a rate of IBD in Australia and New Zealand which is comparable to 
some of the highest rates published in the literature. In the South Island, Canterbury and 
Nelson have some of the highest documented rates of IBD prevalence. In 2004, the 
prevalence in Canterbury was reported as 308.3, 155.2 and 145 /100 000 for IBD, CD and 
UC, respectively whereas the incidence (garnered from a prospectively-enrolled incidence 
cohort in 2004) was 25.2, 16.5 and 7.6/100 000 for IBD, CD and UC, respectively.
54
 
Information from unpublished data (personal communication RBG) reports an IBD 
prevalence of 389/100 000 in Nelson. Suggesting a similarly high disease burden across the 
Tasman Sea, a prospective, population-based study conducted in Geelong, within the 
Australian state of Victoria, in 2007 revealed incidence rates of 17.4 and 11.2 per 100 000 for 





 reported a significant increase in the incidence of Crohn’s disease in 
Victorian children, in Australia. Between 1971 and 2001, the incidence rate increased from 
0.128 to 2.0 per 100 000 children aged 16 years and under, per year when reviewed 
retrospectively. From the same group, a more recent retrospective review conducted over a 
sixty-year period reported an 11-fold increase in the incidence of paediatric UC between 
1950 and 2009.
79
 Of particular interest, this study revealed that the majority of children 
presenting with UC nowadays have “extensive colitis” (as the author’s described it) at intial 
presentation, a change from previous. They also found an increasing proportion of their 
cohort had extra-intestinal, namely hepatic, involvement at the time of diagnosis. As the 
authors conceded however, the latter two findings may be a reflection of less-stringent 
diagnostic modalities available in previous decades. That stated, the rising incidence over the 
last 20 years (during which ileocolonoscopy has been the gold standard for diagnosis) may 






To date, there is only a single-published study of the epidemiology of paediatric IBD in New 
Zealand. Published in 2008, but conducted between 2002 and 2003, a prospective study
55
 was 
undertaken via the New Zealand Paediatric Surveillance Unit (NZPSU) with the aim of 
ascertaining the incidence, presentation and initial management of paediatric IBD in the 
country. In survey form (with the attendant disadvantage of reliance on voluntary reporting), 
all new cases of IBD diagnoses in children under the age of 15 years made in New Zealand 
between January 2002 and December 2003 were notified to the NZPSU. The estimated 
incidence rates over the study period were 2.9, 1.9 and 0.2 per 100 000 children per year for 
IBD, CD and UC, respectively. Among the 52 new cases of paediatric IBD included in the 
study, 66% consisted of CD, 17% UC and 17% IBDU. The study authors found, among other 
things, that 5-aminosalicylic acid agents followed by systemic steroids were the most 
common initial therapeutic agents – employed much more commonly than nutritional 
therapy. The study concluded that the incidence of paediatric IBD was “comparable but at the 










































2.1 INTRODUCTION TO THE PINZ STUDY 
This research was funded by Freemasons New Zealand in the form of a Freemasons Post-
Graduate Fellowship in Paediatrics and Child Health - awarded to the author for the year 
2015. This Fellowship entails a position with the University of Otago at the level of a 
Research Fellow for a fixed-term during which remuneration is provided by way of salary 
and a modest budget to cover subsidiary expenses. 
This research formed part of the author’s own advanced training in the field of paediatric 
gastroenterology undertaken through the Royal Australasian College of Physicians. The 
choice of paediatric IBD as a research topic was informed by two factors: 1) the author’s 
interest in the field because of its clinical appeal and its depth of research potential, and 2) the 
strong research credentials in the field of gastroenterology in general, and IBD in particular, 
of both the supervisors’ of this work.   
As discussed in Chapter 1, the burden of paediatric IBD is increasing globally. The PINZ 
study hoped to create a sustainable means of monitoring the natural history of paediatric IBD 
in New Zealand. To achieve this, collaboration was sought and obtained from all paediatric 
gastroenterologists in the country, either personally or by proxy. It was hoped that the 
establishment of the PINZ study would allow for multiple, prospective, retrospective, and 
case-control studies into the epidemiology of paediatric IBD and surrogates of the disease 
such as surgery, pharmacotherapy and other therapy.  
 
2.2 SPECIFIC AIMS OF THIS THESIS 
It is the author’s ambition that the PINZ study and associated database will continue beyond 
the duration of this Master in Medical Science (MMedSci) research degree. With that in 
mind, it was decided that while some of the aims of the PINZ project were medium-term in 
outlook, a number of them had to be drawn up and achieved within the 12-month period that 
this degree was undertaken. 
It is the aims specific to that latter category which are outlined below: 
1. To evaluate the annual incidence and disease phenotype of paediatric IBD in 
Canterbury over the last 20 years. This project, all of the author’s clincial 
experience and much of that of his supervisors’ was based in Christchurch. It was 
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hypothesised, on the basis of clinical exposure, that there was likely to be an increase 
in the annual incidence of paediatric IBD in recent times, in keeping with patterns 
observed elsewhere. 
 
2. To evaluate the point prevalence and phenotype of paediatric IBD in New 
Zealand on 30 June 2015. The only paediatric gastroenterology unit in the South 
Island, which is in Christchurch, works in close collaboration with the main (and only 
other) paediatric gastroenterology unit in the country, based at Starship Children’s 
Hospital Auckland. Consensus hypothesis was that the prevalence of paediatric IBD 
in the country is comparable to places which report some of the highest rates 
available in the literature. 
 
3. To prospectively evaluate the incidence and phenotype of paediatric IBD in New 
Zealand in 2015. One of the aims of the PINZ study was to establish a database into 
which demographic, phenotypic and clinical information on every patient diagnosed 
with paediatric IBD in New Zealand would be prospectively entered. The year 2015 
was to serve as the pilot for this aim of the project. It was hypothesised that the 
prospective, annual incidence of paediatric IBD in New Zealand would be 
comparable to places which report some of the highest rates available in the 
literature.  
 
2.3 ETHICAL APPROVAL 
Initial approval for the PINZ study was obtained from the Health and Disability Ethics 
Committee (HDEC) of the Ministry of Health. This approval was granted on the explicit 
basis that this was/is a national study. 
Further approval was sought and obtained for the specific purpose of the retrospective 
Canterbury arm of the PINZ study from the Human Research Ethics Committee of the 
University of Otago. Maori consultation was also sought for this part of the PINZ study. 
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Further to that, for the national components of the PINZ study, institutional approval was 
received from the Auckland District Health Board’s Research Office as being representative 




2.4.1 CASE DEFINITION 
A diagnosis of IBD has been accepted, for the purposes of this thesis, when at least one of 
either the Lennard-Jones
1
 or ESPGHAN Revised Porto
80
 criteria has been met. Notes on 
every patient included as a case were reviewed to ensure that a combination of some or all of 
clinical presentation, endoscopic, radiological, histological and pathological findings 
supported the diagnosis of IBD, once other causes of intestinal inflammation, particularly 
infection were ruled out. Those who did not meet the specified criteria were excluded as were 
those whose diagnosis was made at or beyond the age of 16 years. 
For cases in which an initial diagnosis of IBDU was subsequently replaced by one of either 
CD or UC, the latter diagnosis has been accepted as the single IBD type for that patient 
 
2.4.2 IBD CLASSIFICATION 
The evolution of IBD classification systems is discussed in section 1.1.4. As described in 
Chapter 1, since its introduction in 2011 the Paris modification of the Montreal classification 
system (aka the Paris classification system) has become the benchmark tool used by 
descriptive epidemiologists studying paediatric IBD. Therefore in an effort to use a 
universally-acceptable system to aid comparison of this study’s results with those already 
available in the literature, all cases were classified using the Paris system. This system 
incorporates age at diagnosis, anatomical extent of disease involvement as well as disease 
behaviour and impact on growth. 
Each case was classified once on the basis of their worst ever investigation findings. To be 
sure, this meant that for patients who had had their disease “re-staged” since initial diagnosis, 
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the basis of their Paris classification for this study was their most extensive disease 
involvement ever rather than either their initial, or most recent, investigation findings.  
Whilst the Paris classification system takes into account the impact of Crohn’s disease on 
growth, this was not applied to patients in the present study. The reason for this is that 
reliable, chronological growth parameters were not available on all cases, especially the 
oldest among them. Similarly, UC severity according to the Paris system (S0 or S1) was not 
formally noted as all relevant results needed to apply this classification were not available in 
the majority of cases. 
 
2.4.3 CASE RECRUITMENT 
Cases were recruited for the arms of the PINZ study in similar and different methods 
depending on the geographic location. These are described in the individual chapters which 
cover each arm of the study.   
 
2.4.4 OUTLINE OF THIS THESIS AS RELATES TO THE PINZ STUDY 
In Chapter 3, the annual incidence of paediatric IBD in Canterbury between 1996 and 2015 is 
described. A brief insight into the landscape and demography of Canterbury is given. Health 
provision in the region is discussed and case recruitment for this part of the study further 
explained. Specific population figures for the 20-year period the study covers is given. The 
trend in annual incidence over the last two decades is statistically analysed. 
Following that, the cohort that is accounted for in Chapter 3 is further studied in Chapter 4. In 
this latter chapter, demographic features are given and descriptively analysed. Family history 
of IBD data is also presented. The disease phenotypic features of CD and UC in this cohort 
are given. The modalities used to establish diagnosis and the need for surgery among this 
group is also described and analysed. 
In Chapter 5, the point prevalence of paediatric IBD in New Zealand on 30 June 2015 is 
calculated. The methods of case recruitment are explained and the specific population 
estimates (broken down by gender and age ranges) for the date are also given. All of the 
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demographic, phenotypic and surrogate markers of disease discussed in Chapter 4 are also 
presented in Chapter 5 - pertaining to the point-prevalent national cohort. 
In Chapter 6, the prospective, annual incidence of paediatric IBD in New Zealand in 2015 is 
given along with the phenotypic features specific to this cohort. Like in chapters 4 and 5, 
diagnostic modalities employed and surrogates of disease information for this group are also 
presented.  
Finally in Chapter 7, the main findings from each of the results chapters are discussed. Also 
the strengths and weaknesses of the PINZ study are explored while future directions this 































As discussed in section 2.2, based on local clinical experience it was the author’s hypothesis 
that the incidence of paediatric IBD in Canterbury had increased between 1996 and 2015. 
The study done  by RBG in 2004 demonstrated that Canterbury had one of the highest rates 
of CD in the world.
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 A more recent, as yet unpublished study involving both the supervisors 
of this work showed that there was a 1.5 times increase in the incidence of CD  in Canterbury 
between 2004 and 2014. As illustrated at the end of Chapter 1, globally the incidence of 
paediatric IBD is on the rise. 
For those reasons it was decided that the trend of paediatric IBD diagnosis in Canterbury over 
a significant time-frame should be explored. The express goal of this study was to be 
population-based and to ensure this, completeness of data collection was deemed to be of 
paramount importance. For that reason, 1996 was chosen as the start of the study period for 
this retrospective review as it was the year that pathological records became computerised in 
the Canterbury District Health Board (CDHB). It was felt methodologically that most cases 
would be identified through existing databases (explained in section 3.2.2) and therefore the 
pathology records would be especially important in identifying those cases who were not 
captured by the former method while simultaneously providing a means for internal 
validation. 
One reason that the trend in paediatric IBD diagnoses in the region was thought important to 
analyse was to ensure the appropriateness of current and future paediatric gastroenterology 
service provision. Also if the hypothesised high rate of paediatric IBD in Canterbury was 
proven, if could lead to further studies investigating if there are environmental factors unique 
to the region which may be culpable. The effect of migration on the incidence of paediatric 
IBD (if any) was also one thought worth exploring. Canterbury was one of only four regions 
(and the one with the second-largest, after Auckland) to have a net gain of international 
migrants between 1996 and 2014.
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3.1.2 PROVISION OF HEALTH CARE IN CANTERBURY 
New Zealand has a two-tier specialist-level health system comprising publicly-funded and 
private healthcare. The public system affords equal access to core, non-discretionary and 
urgent medical care which is free to all citizens and permanent residents (as well as other 
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selected groups) of the country. The option of pursuing care above and beyond that threshold 
is available in the private sector for a fee.
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  Primary care is provided for by General 
Practitioners to whom a fee is paid by the patient following each consultation. Approximately 
one quarter of New Zealanders under the age of 16 years have private health insurance.
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Public hospital-level care in Canterbury is provided for by the CDHB and the South 
Canterbury District Health Board (SCDHB). The SCDHB provides for the districts in 
Canterbury south of Ashburton. 
Christchurch Hospital is the only tertiary-level paediatric referral centre for the whole of the 
South Island. Timaru Hospital provides general paediatric care although children residing in 
and around Timaru requiring paediatric sub-specialty input are referred to Christchurch. The 
only South-Island paediatric gastroenterologist (and one of the supervisors of this thesis, 
ASD) is based in Christchurch and provides outreach paediatric gastroenterology service to 
the whole of the South Island.  
There is no universal age limit to the provision of paediatric care in New Zealand. In practice, 
some adolescents known to paediatric services are followed up beyond the age of transition 
(which varies with the centre) until such time as their illness is relatively stable and/or their 
level of maturity is felt to be better suited to the care offered by adult services.  
Paediatric gastroenterology care is not available outside of the public system anywhere in the 
South Island. In theory, this should mean that any young person, under the age of 16 years 
and resident in the South Island, with a chronic gastroenterological condition (including IBD) 
should be known to the paediatric gastroenterologist in Christchurch. By extension, his IBD 
database should approximate a population-based cohort. In reality however, less than a 
handful of adult gastroenterologists see peri-pubertal patients with IBD in their private 
practices. Also, though less likely, it is possible that children living outside of Christchurch 
who have IBD are looked after by a general paediatrician with either no or only adult 








In this thesis, paediatric IBD is defined as a diagnosis of either CD, UC or IBDU made in 
someone under 16 years of age – the age cut-off for new referrals to the paediatric service in 
Canterbury and to Starship Children’s Hospital. The description of each of the 
aforementioned diagnoses is given in sections 1.1.1 to 1.1.3. 
 
3.2.1 CASE DEFINITION 
The case definition of paediatric IBD used in the PINZ study is given in section 2.4.1. To be 
included as a case in the arm of the PINZ study described in Chapter 3, patients had to be 
resident in Canterbury (at least at the time of diagnosis) as well as having been diagnosed in 
Canterbury. Patients diagnosed with IBD in centres outside of Canterbury (regardless of their 
residency) were excluded from being cases.  
 
3.2.2 CASE RECRUITMENT 
Two existing databases were initially searched for cases that met the inclusion criteria for this 
section of the thesis. The first of these is an IBD database (part of the separate, but related, 
Crohn’s and Colitis Study) which contains a up-to-date list of every patient in the South 
Island cared for (in some capacity) by ASD. In theory, it should be a reliable resource of 
information on every patient diagnosed with IBD prior to (if still under the age of 16) and 
since, 2009. The other database (known also as the “Canterbury IBD Project”) is the one 
created and maintained by RBG (also a supervisor of this thesis). This latter database 
provided the basis for RBG’s PhD thesis. It contains every patient diagnosed with IBD who 
was resident in Canterbury in 2004, i.e. a prevalent cohort at that point in time. Beyond those 
sources of information, an Excel spreadsheet of patients seen and treated in Christchurch 
Hospital between 1990 and 2015, who were 16 years and under, and who had a clinically-
coded diagnosis of either “Crohn’s”, “ulcerative colitis”, “inflammatory bowel disease or 
IBD” or a slight variation of any of those was obtained from Decision Support at the CDHB. 
Also, with the help of a pathology department research nurse, histology results between 1996 
(when the department started using a computerised results system) and 2015 were sought on 




To ensure a complete capture of patients, every adult gastroenterologist and paediatric 
surgeon practising in Christchurch and Canterbury, respectively was contacted and informed 
about the current study. The vast majority of them either denied providing care for paediatric 
patients or said that the patients younger than 16 years with IBD that they have seen will have 
been referred to Christchurch Hospital. Two adults gastroenterologists admitted to seeing a 
small number of under-16 year olds in their private practice. Patients who met the inclusion 
criteria and cared for by the first of them were notified to the author, whereas the database of 
the second adult gastroenterologist with a paediatric interest was searched with permission, 
and the relevant patients entered into the PINZ database. 
Notes on each identified patient were then examined methodically. Those who did not meet 
criteria for IBD diagnosis or who were diagnosed either outside of the study time period, non-
resident or diagnosed outside of Canterbury, or when older than 16 years of age were 
excluded. In every instance, electronic patient records were studied. If there was any 
ambiguity, the hard-copy case notes were retrieved to ensure accuracy of data collection. 
 
3.2.3 POPULATION FIGURES 
Population estimates for every year between 1996 and 2015 (inclusive) were obtained from 
Statistics New Zealand. The figures reflected the estimated population of people under the 
age of 16 years resident in Canterbury on 30 June of each of those years. The figures obtained 
were broken down by sex and into different age brackets, specifically 0-4 years, 5-9 years, 
10-15 years and 0-15 years.   
 
3.2.4 STATISTICAL ANALYSIS 
All information was analysed descriptively. Age ranges and follow-up period are given as 
median with relevant interquartile (IQR) ranges. The incidence rates were calculated with the 
number of new cases in a calendar year serving as the numerator and the estimated 
population of Canterbury under the age of 16 years, for each of the study years, as the 
denominator. Incidence rates are described per 100 000 persons. Exact binomial confidence 
intervals (CI) for the incidence rates were calculated, using the Byar approximation for 
Poisson distribution, because of the low numbers in some of the age groups. The Mann-
Whitney and Kruskall-Wallis tests were used to compare mean incidence rates between 
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different time frames. Linear regression analysis was performed to evaluate the trend in 
annual incidence rates. Statistical significance was accepted if p<0.05. All statistical analysis 
was performed using GraphPad Prism version 6.00 (GraphPad Software, LaJolla, California).  
 
3.3 RESULTS 
In the following sections, the incidence rate of paediatric IBD in Canterbury is given for each 
year between 1996 and 2015. The trend in annual incidence rates has also been analysed. The 
demographic and disease phenotypic characteristics of the cases have also been studied. 





















Figure 3.1: Order in, and sources from, which data were sought to ascertain incidence of 























In parentheses are the number of new cases obtained from each source. Most cases appeared in multiple databases (data not shown). This 
provided excellent internal validity of the methodology employed. 






















3.3.1 POPULATION OF 0-15 YEAR OLDS IN CANTERBURY, 1996-2015 
The population counts of 0-15 year olds in Canterbury during the study period of 1996-2015 
were obtained from Statistics New Zealand. During this 20-year time frame, four nationwide 
census were carried out – in 1996, 2001, 2006 and 2013. For years where no census was 
conducted, a population estimate of 0-15 year olds as of the 30
th
 of June of each of those 
years was provided by Statistics New Zealand. 
Canterbury had a population increase of 0-15 year olds between 1996 and 2015. In 1996, the 
population of 0-15 year olds in the region was 104 320. That figure had increased to 114 780 
in 2015. There was an annual increase in the population of 0-15 year olds between the years 
of 1996 and 2010. Following the series of earthquakes in Canterbury which began in 
September 2010, there was a downturn in the population of 0-15 year olds (and that of the 
region as a whole) in 2011. Since 2012, the population has 0-15 years old in Canterbury has 
demonstrated an upward trend. 
Over the 20-year study period, the mean population of 0-15 year olds in Canterbury was 110 
716. The minimum number of 0-15 year olds in Canterbury during the study period was in 
the year 1996, whereas the maximum was in 2010 when the population was 116 520.   
 
Figure 3.2: Age-specific population estimate in Canterbury on 30 June for 1996-2015 
 
 




























































































1 0 0 0 0 0
1 0 5 0 0 0
1 1 0 0 0 0
1 1 5 0 0 0
1 2 0 0 0 0
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Table 3.1: Annual incidence of paediatric IBD in Canterbury, 1996-2015 









population estimate  
Canterbury PIBD incidence 
(per 100 000) [95% CI] 
1996 3 2 1 1*  104 320 2.88 [0.58-8.40] 
1997 5 3 2 0 105 210 4.75 [1.53-11.09] 
1998 7 4 3 1*  105 860 6.61 [2.65-13.62] 
1999 3 3 0 0 106 110 2.83 [0.57-8.26] 
2000 3 2 2** 0 106 420 2.82 [0.57-8.24] 
2001 3 3 0 0 106 840 2.81 [0.56-8.20] 
2002 4 4 0 0 107 920 3.70 [1.00-9.49] 
2003 10 9 1 0 109 190 9.16 [4.39-16.84] 
2004 4 3 1 0 110 620 3.62 [0.97-9.26] 
2005 8 8 0 0 111 550 7.17 [3.09-14.13] 
2006 10 8 2 0 112 490 8.88 [4.26-16.35] 
2007 11 10 1 0 113 390 9.70 [4.84-17.36] 
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2008 9 8 1 0 114 250 7.87 [3.60-14.95] 
2009 7 7 0 0 115 350 6.07 [2.43-12.50] 
2010 14 14 0 0 116 520 12.01 [6.56-20.16] 
2011 10 9 0 1 114 260 8.75 [4.19-16.10] 
2012 8 6 2 0 112 390 7.12 [3.07-14.03] 
2013 12 11 1 0 112 980 10.62 [5.48-18.55] 
2014 15 15 0 0 113 870 13.17 [7.37-21.73] 
2015 15 14 1 0 114 780 13.06 [7.31-21.56] 
* case subsequently reclassified as CD 
** one of these cases subsequently reclassified as CD 
IBD: inflammatory bowel disease CD: Crohn’s disease UC: ulcerative colitis IBDU: inflammatory bowel disease unspecified PIBD: paediatric 
inflammatory bowel disease 
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3.3.2 ANNUAL INCIDENCE OF PAEDIATRIC IBD IN CANTERBURY, 1996-2015 
The annual incidence of paediatric IBD in Canterbury has shown an overall increase over the 
20-year study period. There was a greater than four-fold increase in the incidence rate 
between the first and last years of the study period – the incidence of paediatric IBD in 
Canterbury in 1996 being 2.88/100 000 (95% CI 0.58-8.40) versus 13.06/100 000 (7.31-
21.56) in 2015. The lowest annual incidence over the study period was 2.81/100 000 (0.56-
8.20) which was the rate in 2001. The highest annual incidence rate was in 2014 - 13.17/100 
000 (7.37-21.73).  
The mean annual incidence of paediatric IBD in Canterbury between 1996 and 2015 was 
7.18/100 000 (5.55-8.81). Over the last ten years of the study period (2006-2015) the mean 
annual incidence was 9.73/100 000 (7.97-11.48) whereas for the last five years of the study 
period (2011-2014) the mean annual incidence was 10.54/100 000 (7.25-13.84). 
When the mean annual incidence rates between five year time-frames were analysed, a 
statistically-significant increase was noted (Figure 3.3). There was also a significant increase 
in the difference between the mean annual incidence of paediatric IBD in Canterbury 
between 1996-2000 and 2011-2015 (Figure 3.3). Linear regression analysis revealed a 
statistically-significant increase in the annual incidence rates over the 20-year study period 













Figure 3.3: Mean annual incidence (± SD) of paediatric IBD in Canterbury in five-year 







































Mann-Whitney test – p<0.05; difference in mean incidence in 1996-2000 and 2011-2014 











Figure 3.4: Linear regression analysis of annual incidence over time 
T r e n d  o f  P I B D  i n c i d e n c e  i n   C a n t e r b u r y ,  1 9 9 6 - 2 0 1 5


















































3.4 KEY FINDINGS FROM CHAPTER 3 
1. The annual incidence of paediatric IBD in Canterbury has more than quadrupled over 
the two decades studied 
 
2. The overall ratio of paediatric CD to paediatric UC between 1995 and 2015 was 8.4:1 
 
3. The incidence of paediatric IBDU over the study period was very low – three cases in 































DEMOGRAPHIC AND DISEASE CHARACTERISTICS OF 
















In Chapter 3, the incidence of paediatric IBD in Canterbury over a 20-year time frame is 
presented. Aside from identifying patients who met the case definition (as in section 2.4.1) to 
merely include in the calculations of incidence per year, pertinent demographic and disease 
phenotypic information was gathered on each patient. 
As the methodology used to identify patients for this retrospective study were robust, the 
demographics and disease characteristics of this cohort should reflect those of the Canterbury 
population. 
Two important areas of information could be obtained from analysis of this data: first, 
whether or not the demographics and disease characteristics of those affected by paediatric 
IBD in Canterbury has changed over the course of time, and secondly, whether or not the 
demographics and disease characteristics of paediatric IBD in Canterbury is in keeping with 
that described in other locations in the world. 
It was hypothesised that Canterbury’s data would mirror those from descriptive 
epidemiological studies conducted elsewhere. It was also felt that those diagnosed with IBD 
in the paediatric age range would display, in general, a more extensive and severe phenotype 
than their adult counterparts. There were unlikely to be true changes of disease phenotype 
over time with the exception of greater recognition of upper gastrointestinal and small bowel 
involvement in CD as a corollary of upper gastrointestinal endoscopy and high-quality small 




4.2.1 CASE RECRUITMENT 
The methods of case recruitment are as described in section 3.2.2. Once identified, medical 
records for each patient were studied. Mostly this involved looking through the computerised 
patient information system (namely Health Connect South) of the CDHB. Endoscopy, 
histology and radiology results were looked at as were clinic letters which served as records 
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of Paediatric, Gastroenterology and Surgery outpatient visits. Discharge documentation from 
relevant inpatient admissions were also explored. 
For cases where there was insufficient or incomplete information available on Health 
Connect South, patient notes were obtained from Clinical Records at the CDHB and this 
compensated for any shortfall in the computerised records. 
 
4.2.2 IBD DEMOGRAPHICS AND SURROGATES OF DISEASE SEVERITY 
For each case included in this study, basic demographic information including ethnicity was 
collected. Being retrospective in nature, and in keeping with the ethical approval obtained for 
this study (which was granted on the pretext that patients would not be contacted directly), 
certain presumptions were made with regards to the collection of ethnicity data.  
It is acknowledged that the recording of patient ethnicity data in hospital-based patient 
management systems is not always accurate. Furthermore, an individual may identify 
differently from the ethnicity of one or both parents (particularly in instances of mixed 
parentage) or may choose to identify with a particular ethnicity on the basis of ancestral 
lineage - a fact which may not always be recorded or recordable.  
Ethnicity data in this study was gathered from Health Connect South. For patients who were 
concurrently enrolled in the aforementioned Crohn’s and Colitis Study, individual parent 
ethnicities were recorded, where available. In the majority of cases, each patient had only one 
ethnic group listed. In instances where more than one was available, the patient has been 
classified as belong to all applicable ethnic groups. The ethnic groups used in this study are in 
keeping the recognised major ethnic groups in New Zealand, namely European, Maori, 
Asian, Pacific peoples and Middle Eastern/Latin American/African (MELAA).
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Any positive family history of IBD, where noted clinically, was documented in the PINZ 
database. Also, diagnostic modalities employed leading up to diagnosis were recorded. The 
presence of extra-intestinal manifestations of IBD were recorded as was a history of any 
surgical intervention directly related to IBD. 
In the majority of cases, drug history was obtained. Specifically the list of any medications 
used either in the past or currently to manage the patient’s IBD was recorded. Where 
possible, the reasons for stopping a drug were documented. Also the use of steroids and 
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exclusive enteral nutrition to induce IBD remission, at any point in the course of disease was 
noted.  
 
4.2.3 DATA RETRIEVAL AND MANAGEMENT 
The basic demographic and disease phenotypic information on each patient included in the 
PINZ study were obtained by the author. This ensured uniformity of disease classification. 
Any uncertainty regarding the accuracy of disease phenotyping with regards to specific cases 
was clarified after discussion with one of the thesis supervisors, ASD.  
All information gathered was entered into a Microsoft Access database entitled “Paediatric 
IBD in New Zealand (PINZ) Study”. The author was the only person who had access to this 
database. The form which was filled out in this database consisted of five tabs namely, 
Patient Demographics, Family and Contact Details, IBD – At Diagnosis (which consisted of 
fields pertaining to type of IBD, year of diagnosis, diagnostic modalities used and lead 
clinician under whose care the patient was/is), IBD Paris classification and IBD – Specifics 
(which consisted of fields pertaining to extra-intestinal manifestations, IBD-related surgery, 
drug, steroid and EEN history).  Each case entered into the PINZ study database had a unique 
non-identifiable descriptor known as “PIBD code’. 
 
4.2.4 STATISTICAL ANALYSIS 
All data were analysed descriptively. Comparisons between groups were performed using the 
paired t-test. Statistical significance was accepted if p<0.05. All statistical analysis was 
performed using GraphPad Prism version 6.00 (GraphPad Software, LaJolla, California).  
 
4.3 RESULTS 
Between 1996 and 2015, there were 161 new diagnoses of paediatric IBD made in 
Canterbury. These consisted of 143 cases of CD (two of which were classified as IBDU and 
one of which UC, initially, before subsequently being reclassified as CD), 17 cases of UC and 
one case of IBDU. The annual incidence over that 20-year time frame is described and 
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analysed in Chapter 3. The median follow-up period, calculated as whole years between the 
year of diagnosis and 31 December 2015, was 7 years (IQR 3-12 years).  
 
4.3.1 GENDER DISTRIBUTION OF PAEDIATRIC IBD 
There were 100 (62.1%) males diagnosed with IBD over the 20-year study period. Of the 143 
cases of CD, 91 (63.6%) were male and the rest female whereas nine (52.9%) of the 17 cases 
of UC were male. The sole case with IBDU was female. The male preponderance among 
paediatric IBD, CD and UC was non-significant (p=0.18). 
 
4.3.2 PAEDIATRIC IBD IN CANTERBURY BY ETHNICITY 
The majority of patients included in the study identified as being European (86.5%). Five 
(3.1%) identified as Maori, six (3.7%) identified as Asian and two (1.2%) as Pacific Islander. 
In fourteen (8.7%) cases, ethnicity data were not available. To provide some perspective, in 
the 2013 census 86.9% of the Canterbury population was European whereas the percentage of 
Maori, Asian and Pacific Islander peoples was 8.1, 6.9 and 2.5, respectively.
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 In the majority 
of cases, each patient had only one ethnic group listed. In instances where more than one was 
available, the patient has been classified as belonging to all applicable ethnic groups 
 
4.3.3 FAMILY HISTORY OF IBD 
Among the study cohort, 40 (24.8%) patients had a documented family history of IBD. In 14 
cases, the affected family member was a first-degree relative whereas in 11 cases the affected 
family member was a second-degree relative. In 14 cases the affected family member was a 
third-degree relative or greater whereas in one case the affected family member was not 
documented. In the ten instances where there was more than one family member affected, the 






4.3.4 PARIS CLASSIFICATION OF PAEDIATRIC IBD IN CANTERBURY 
All cases with CD were classified according to their disease location i.e. whether they had 
only ileal involvement, only colonic involvement or ileo-colonic involvement. Note was 
made of upper gastrointestinal and peri-anal involvement in patients who had ileal and/or 
colonic CD. In four (2.8%) instances, patients had CD affecting either their upper 
gastrointestinal tract and/or peri-anal region without any lower intestinal involvement.  
CD behaviour was also stratified along inflammatory, stricturing and/or penetrating lines. 
Age at CD diagnosis was dichotomised to either below or above 10 years of age (see Table 
3.1).  
The extent of UC involvment was also classified according to the Paris criteria. Specifically 
note was made of rectal UC, disease distal to the splenic flexure, disease distal to the hepatic 
flexure or pan-colonic UC. 
Of the 143 cases of CD, 107 (74.8%) were diagnosed over the age of 10 years. 27 (18.9%) 
patients had only ileal involvement, 31 (21.7%) had only colonic involvement whereas 81 
(56.6%) had ileo-colonic involvement. Two (1.4%) each had only peri-anal and only upper 
gastrointestinal CD involvement.   
The vast majority (79.8%) of cases had inflammatory CD with 18 (14.5%), 4 (3.2%) and 3 
(2.4%) patients having a stricturing, penetrating and stricturing and penetrating phenotype, 
respectively. 66 patients with CD (53.2%) had upper GI involvement whereas 23 (18.5%) had 
peri-anal involvement. 
Nearly one fifth of patients with CD had peri-anal involvement whereas 80 (55.9%) had 
known upper GI involvement. The latter figure is likely an under-representation as in 33 
cases of CD, upper GI endoscopy was either not performed or the result not available. 
Of the cases with UC, three (17.6%) had proctitis, one (5.9%) had left-sided colitis, ten 







Table 4.1:  Paris classification of 143 children with Crohn’s disease in Canterbury 






L1          L2          L3         Only     
                                          Upper  
                                          GI/PA                                           
L1          L2          L3          Only 
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6            7            21          1               
0            0            0            0 
0            1            0            0 
0            0            0            0 
2            4            13          0  
0            0            0            0 
0            0            0            0 
2            3            6            0                                 
2            1            2            1 
0            1            7            1 
 
 
12          18          49          2 
4             4            8           1 
3             0            1           0 
2             1            2           0 
8             9            37         1 
2             1            0           0 
0             0            2           1 
5             8            5           1 
6             5            16         0 
4             4            10         1 
 
 
A1a: Diagnosed under 10 years of age   A1b: Diagnosed between ages 10-17 years   L1: ileal 
L2: colonic   L3: ileo-colonic   L4a: upper GI disease proximal to ligament of Trietz 






4.3.5 SURGERY FOR PAEDIATRIC IBD IN CANTERBURY 
Of the 161 cases with paediatric IBD included in the study, 36 (22.4%) required IBD-related 
surgery. The types of surgery undergone by the study participants with CD is listed in Table 
4.2. 32 patients who required surgery had CD while the rest had UC. 23 patients who 
underwent surgery had intestinal resections while ten patients had surgery for peri-anal CD.  
All four patients with UC who underwent surgery had colectomies. Two had ileo-anal 
pouches formed whereas one was left with a rectal stump and another had an end-ileostomy 
formed. 
 
4.3.6 EXTRA-INTESTINAL MANIFESTATIONS OF PAEDIATRIC IBD IN 
CANTERBURY 
Of the 161 patients newly-diagnosed with paediatric IBD between 1996 and 2015, 22 
(13.7%) had a history of extra-intestinal involvment. All of these patients had CD. The 
breakdown of extra-intestinal manifestations among the study cohort is given in Table 4.3. 
Rheumatological involvment included non-specific IBD-related arthralgia, systemic arthritis 
and ankylosing spondylitis. Dermatological involvement consisted of erythema nodosum as 
well as non-specific cutaneous manifestations. Hepato-biliary involvement ranged from non-
specific liver dysfunction to Type I autoimmune hepatitis and primary sclerosing cholangitis. 
Orofacial involvement was considerend in this study for cases with mouth ulcers as well as 
those of orofacial granulomatosis (with intestinal IBD); orofacial granulomatosis patients 
without intestinal inflammation were excluded from the PINZ study. Ophthalmological 
involvement consisted of episcleritis. 
 
4.3.7 INVESTIGATION MODALITIES UTILISED AT TIME OF DIAGNOSIS 
Of the 161 new diagnoses of paediatric IBD between 1996 and 2015, complete diagnostic 
information was available on 143 (88.8%) of them. Of these, all had colonoscopy and 105 
(73.4%) had an upper GI endoscopy at the time of diagnosis. Two of the 137 children were 
strongly suspected of having IBD at laparoscopy and this was confirmed at endoscopy shortly 
thereafter. Another patient had a CT abdomen suggestive of CD, which was again confirmed 
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endoscopically. One patient was diagnosed on small bowel imaging in spite of normal 
endoscopy and histology in the context of a suggestive clinical and biochemical presentation. 
Fifty-seven (39.9%) of the 143 cases had dedicated small-bowel imaging at the time of 
diagnosis, accepted as being within six months of a formal diagnosis. Thirty-eight of these 
patients had magnetic resonance enterography, thirteen had barium meal and follow-through, 
three had capsule endoscopy and a further three had a CT abdomen, as part of their work-up, 























Table 4.2: Surgery undergone by CD patients included in study 
Type of surgery 
 
Number of patients  
Ileocolic resection 8 
(Limited) right hemicolectomy 6 
Incision and drainage of peri-anal 
abscess(es) and/or laying open and/or 
placement of Seton for perianal fistula 
10 







Rectal dilatations 1 
* Excluding ileo-colic resection  
** Excluding ileo-colic resection and limited (right) hemicolectomy 
 Each patient is counted only once for each time they had a specific surgical intervention; some patients 
had more than one type of intervention 
 
Table 4.3: Extra-intestinal manifestations of paediatric IBD (all cases with CD) in Canterbury 
Organ system involved 
 




















4.4 KEY FINDINGS FROM CHAPTER 4 
1. A non-significant male preponderance existed for cases of paediatric IBD (and CD 
and UC, respectively) between 1996 and 2015 
 
2. Over the study period, paediatric IBD was mainly a European/caucasian disease 
although Maori, Pacific Island and Asian children in Canterbury were also affected 
 
3. Nearly one quarter of all children newly diagnosed with paediatric IBD between 1996 
and 2015 had a documented family history of IBD 
 
4. Nearly ¾ of new paediatric CD diagnoses were made in children 10 years or older; 
over half had ileo-colonic CD; approximately 80% had an inflammatory phenotype 
 
5. Nearly 20% of CD diagnoses had peri-anal involvement whereas over 55.9% had 
upper GI involvement (the latter figure likely being an under-estimate) 
 
6. Nearly 60% of children newly-diagnosed with UC in Canterbury over the study 
period had pan-colonic involvement 
 
7. Greater than one in five of every child diagnosed with IBD in Canterbury between 
1996 and 2015 required surgery over a median follow-up period of seven years 
 
8. In all cases where information was available, IBD diagnosis was confirmed using 
fibreoptic endoscopy (with almost ¾ having upper gastrointestinal endoscopy as well 




















POINT PREVALENCE, DEMOGRAPHY AND PHENOTYPE OF 















Primarily on the basis of clinical experience, it was hypothesised at the outset of the PINZ 
project that the prevalence of IBD among the paediatric age-group in New Zealand was 
substantial. Aside from a two-year prospective survey
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 done over a decade ago, no formal 
study on the burden of this disease, nationally and among this age group has ever been done. 
Aside from noting the trend, demography and phenotype of paediatric IBD in Canterbury, the 
other aims of the PINZ project were to ennumerate the point prevalence and prospective 
incidence of the same in New Zealand, as a whole. The demographics and phenotype of 
paediatric IBD nationally would also be defined. 
The fact that tertiary paediatric care in New Zealand is centralised was felt to naturally lend 
itself to this type of study. At the time of writing, there were five full-time paediatric 
gastroenterologists who practice in New Zealand. Four of them are based at the only 
specialised paediatric centre in the country – Starship Children’s Hospital in Auckland, and 
the other (ASD)  is based at Christchurch Hospital in Canterbury. Starship is the referral 
centre for paediatric gastroenterology in the North Island whereas Christchurch Hospital 
fulfills the same role in the South Island. 
The PINZ study, while based and run out of the University of Otago, Christchurch, had and 
continues to have the full co-operation of the paediatric gastroenterology service in 
Auckland.   
 
5.1.2 PROVISION OF HEALTHCARE IN NEW ZEALAND 
Most healthcare in New Zealand is sought and provided for within the public system. There 
are 20 district health boards (DHBs) which directly or indirectly provide primary, secondary, 
tertiary as well as auxilliary health and disablity care for the population within their districts. 
Some of this care is funded by the local DHB but provided for either in the private sector or 
in another DHB. Accident services in New Zealand are funded by the Accident 
Compensation Corporation (ACC). Elective health care above and beyond a certain threshold 
is attainable for a fee in the private sector. 
Paediatric care in New Zealand is provided for up to the age of 15 or 16 years, depending on 
the centre. Paediatric patients with chronic conditions are sometimes transferred to adult 
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services beyond that age once their condition is clinically-stable and/or they have reached a 
maturity felt to be better-suited to adult medicine. In New Zealand, specialist paediatric 
gastroenterology care is only available in Auckland and Christchurch, and within the public 
system. One of the paediatric gastroenterologists who works at Starship Children’s Hospital 
also has a private practice. As discussed in Chapter 3, there does exist, a difficult-to-quantify 
but likely small, cohort of young people, eligible for paediatric gastroenterology care by 
virtue of their age who are under the sole care of adult gastroenterologists or physicians.  
All children with IBD, including those who live outside of Auckland and Christchurch, 
should have paediatric gastroenterology input into their medical care. In practice, depending 
on local circumstances, the extent of tertiary input may range from occasional review at an 
outreach clinic conducted by the paediatric gastroenterologist to transfer of the patient to one 
of the referral centres for initial work-up, diagnosis and management and occasionally, even 
follow-up appointments. For the former group, whilst face-to-face review with the paediatric 
gastroenterologist may only occur once every few months, these patients invariably have a 





5.2.1 CASE DEFINITION  
The definition of IBD is as described in section 2.4.1. Further to that, for inclusion into the 
part of the PINZ study described in this chapter, cases had to have been both, under the age of 
16 years and formally diagnosed with IBD, on or before 30 June 2015. 
 
5.2.2 CASE RECRUITMENT AND DATA MANAGEMENT 
All paediatric patients with IBD in the South Island are currently enrolled in the database of 
the Crohns and Colitis Study referred to in section 3.2.2. This database was searched and 
every patient with a confirmed diagnosis of IBD who was under 16 years of age on 30 June 
2015 was included as a case for this part of the PINZ study. 
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All patients in the North Island with paediatric IBD are known to one of the paediatric 
gastroenterologists at Starship Children’s Hospital. With the close co-operation of the head of 
paediatric gastroenterology in that unit, each of the four Starship Hospital Paediatric 
Gastroenterologists compiled a list of every patient with IBD known to their service. This list 
comprised patients resident in Auckland as well as those who lived in other North Island 
locations and attended paediatric gastroenterology outreach clinics locally.  To ensure a 
complete capture of every patient with IBD known to the paediatric gastroenterology service 
in Starship Children’s Hospital, the search done in compiling the list was based on a coded 
diagnosis of IBD or one of its sub-types. 
With the co-operation of the head of paediatric gastroenterology at Starship Children’s 
Hospital, members of the New Zealand Society of Gastroenterology (NZSG) were made 
aware of the PINZ study and invited to approach either the head of paediatric 
gastroenterology at Starship Hospital and/or the author if they had any patients under their 
care in private practice who met inclusion criteria for the study. Further to that, key clinicians 
working in two of the biggest private adult gastroenterology practices in Auckland as well as 
gastroenterologists with significant private practices in Wellington and the Hutt Valley were 
individually approached about potential patients meeting inclusion criteria for the current 
PINZ study. The clinicians approached in Auckland and the Hutt Valley denied having any 
patients under 16 years of age cared for exclusively in their private practices. The 
gastroenterologist in Wellington kindly offered relevant details on patients under 16 years 
whom he managed in the private sector, many of whom were already enrolled in the PINZ 
study by virtue of being jointly cared for by the paediatric gastroenterologist at Starship 
Hospital who provided outreach service to the Wellington region. It was thought highly 
unlikely, following discussion between the author, the supervisors of this work and the head 
of paediatric gastroenterology at Starship Hospital, that any other centres in the North Island 
would have children with IBD cared for exclusively in the private sector. Therefore no adult 
gastroenterologist in these areas was individually approached. 
Following ethical approval, the department of paediatric gastroenterology in Auckland 
organised for the author to obtain remote (i.e. outside of Auckland) access to one of the 
ADHB’s computerised patient information systems, namely 3M. 
Clinical correspondence on each patient on the aformentinoed list was then explored and only 
patients who met the inclusion criteria were included into the PINZ database (per section 
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4.2.3). This list was updated through the course of 2015 as new diagnoses of paediatric IBD 
were made by the different paediatric gastroenterologists.  
Disease phenotypic and demographic features on each patient was collected. Information on 
the South Island cohort was obtained as is described in sections 4.2.1 and 4.2.2. For patients 
living in the North Island, the same information was obtained from 3M. Ethnicity data on the 
latter subset were gathered from Concerto (another computerised patient information system 
of the ADHB) by an administrative assistant based in Auckland. Concerto lists only one 
ethnic group for each patient.  
 
5.2.3 POPULATION FIGURES  
The last New Zealand census was done in 2013 by Statistics New Zealand. In years where no 
census is undertaken, estimated population data are made available. The estimated New 
Zealand population of people between 0-15 years of age on 30 June 2015 was obtained from 
Statistics New Zealand for the purposes of this portion of the study. These figures were 
broken down by sex and further broken down by age range, specifically, 0-4 years, 5-9 years, 
10-15 years and 0-15 years (see Table 5.1). The population estimates for 0-15 year olds by 
regions in New Zealand was also obtained. 
 
5.2.4 STATISTICAL ANALYSIS 
All information was analysed descriptively. Numerical data are given as median, reported 
always with the relevant inter-quartile range (IQR). Comparisons between groups were 
performed using the paired t-test. Statistical significance was accepted if p<0.05. All 















10-15Years Under 16 
Years 
Male 157,530 161,780 182,290 501,600 
Female 149,160 153,350 173,680 476,200 
Total 306,690 315,130 355,970 977,800 
Source: Statistics New Zealand 
 
5.3.1 POINT PREVALENCE OF PAEDIATRIC IBD IN NEW ZEALAND, 30/6/15 
On 30 June 2015, there were 212 people under the age of 16 years with IBD living in New 
Zealand. 161 (75.9%) of these cases had CD, of whom four were initially diagnosed with 
IBDU before a subsequent reclassification to CD. Of the remaining cases, 32 (15.1%) had 
UC; three of those patients were initially diagnosed with IBDU. There were 19 (9.0%) 
patients with IBDU on 30 June 2015. 
Incorporating the estimated population figure of 0-15 year olds in New Zealand on that date, 
the point prevalence of paediatric IBD was 21.7/100 000 (18.9- 24.8) people under the age of 
16 years. The point prevalence of CD, UC and IBDU respectively was 16.5/100 000 (14.0-
19.2), 3.3/100 000 (2.2-4.6) and 1.9/100 000 (1.2-3.0) New Zealanders under the age of 16 
years. 
 
5.3.2  REGIONAL POINT PREVALENCE OF PAEDIATRIC IBD IN NEW ZEALAND 
On 30 June 2015, paediatric IBD was prevalent in every region in New Zealand. The region 
with the highest point prevalence of paediatric IBD was Marlborough with 57.9/100 000 
children, whereas the Bay of Plenty had the lowest prevalence rate of 1.5/100 000 children. 
There were generally higher point prevalence rates in the South Island compared with the 
North Island. The region with the highest prevalence rate in the North Island (Wellington – 
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22.9/100 000 children) had a rate which was lower than all but one of the regions in the South 
Island. 
 
Table 5.2: Distribution of paediatric IBD by regions in New Zealand on 30/6/15 



















 The “Others” rows consist of regions where the number of resident children with IBD was less than 
five. These regions have been grouped together to ensure deidentification of the affected patients.  
 The North Island regions included in “Others” are Hawke’s Bay, Gisborne, Taranaki, Manawatu-






















































5.3.3 GENDER DISTRIBUTION OF PAEDIATRIC IBD IN NEW ZEALAND 
There were 129 (60.6%) boys affected with IBD in New Zealand on 30 June 2015 giving a 
male to female ratio of 1.6:1. The male to female ratio of the CD cohort was 1.8:1 with 103 
affected males. The same ratio for UC and IBDU was 0.7:1 and 2.2:1 respectively, with 13 
boys affected with each. There was no significant difference between the genders for either 
paediatric IBD in total, or any of its subtypes (p=0.24). 
 
5.3.4 AGE DISTRIBUTION OF PAEDIATRIC IBD IN NEW ZEALAND 
The median age of children and young people affected with IBD in the country on 30 June 
2015 was 13.2 years (10.8-14.8 years). The median age of patients with paediatric IBD by 
gender was 13.2 years (10.9-14.9 years) and 13.2 years (10.6-14.7 years), for males and 
females respectively. 
The median age of those affected by CD, UC and IBDU was 13.5 years (11.1-15.0 years), 
12.2 years (9.6-13.8 years) and 12.7 years (9.5-14.0 years), respectively. 
 
5.3.5 ETHNIC DISTRIBUTION OF PAEDIATRIC IBD IN NEW ZEALAND 
184 (86.8%) of the 212 patients included in this arm of the PINZ project identified as 
European or had at least one European parent. Nine (4.2%) patients identified as Maori or 
had at least one Maori parent. 21 (9.9%) patients identified as Asian or had at least one Asian 
parent whereas three (1.4%) patients identified as Pacific Islander (or had at least one Pacific 
Islander parent) and three (1.4%) identified as Middle Eastern.  
 
5.3.6 FAMILY HISTORY OF IBD 
46 (21.7%) of the 212 patients with paediatric IBD in New Zealand on 30 June 2015 had a 
positive family history of IBD. In 21 cases, the affected family member was a first-degree 
relative whereas in nine cases the affected family member was a second-degree relative. In 15 
cases the affected family member was a third-degree relative or greater whereas in one case 
the relationship of the affected family member to the case was not documented. In the 13 
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instances where there was more than one family member affected, the closest degree of 
kinship was noted for the purposes of this study. 
 
5.3.7 PARIS CLASSIFICATION OF PAEDIATRIC IBD IN NEW ZEALAND 
Cases with CD and UC were stratified according to the Paris classification system for 
paediatric IBD as discussed in section 2.4.2. 90 (55.9%) of the cases with CD were diagnosed 
aged 10 years or over. Ileo-colonic CD was the most common lower gastrointestinal tract 
location with 87 (54%)  of the included patients affected. 116 (72%) of CD patients had 
upper gastrointestinal tract involvment whereas 28 (17.4%) had peri-anal involvement. 145 
(90.1%) had inflammatory CD whereas ten (6.2%), four (2.5%) and two (1.2%) had a 
stricturing, penetrating and stricturing and penetrating phenotype respectively. 
21 (65.6%) of the 32 cases with UC had pan-colonic involvement. There were five (15.6%) 
patients who had proctitis (E1), four (12.5%) who had left-sided colitis (E2) whereas two 




















L1          L2          L3         Only     
                                          Upper  
                                          GI/PA                                           
L1          L2          L3          Only 
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10          21          30          2               
1            1            4            0 
0            1            0            0 
0            0            1            0 
4            13          24          0  
0            0            1            0 
1            3            1            0 
4            6            9            1 
2            1            0            1 
1            4            3            2 
 
17          14          49          2 
1             2            1           0 
2             0            1           0 
0             0            1           0 
10           11          39         0 
2             0            0           0 
0             1            4           2 
7             3            7           0 
1             1            2           0 
3             4            10         1 
 
A1a: Diagnosed under 10 years of age   A1b: Diagnosed between ages 10-17 years   L1: ileal 
L2: colonic   L3: ileo-colonic   L4a: upper GI disease proximal to ligament of Trietz 
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E 1  -  u lc e ra tiv e  p ro c tit is
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5.3.8 SURGERY FOR PAEDIATRIC IBD IN NEW ZEALAND 
Among all children and young people under the age of 16 years with IBD in New Zealand on 
30 June 2015, 31 of 212 (14.6%) had a history of requiring surgery on account of their IBD. 
Of these, 26 had CD and the rest, UC. The median period of follow-up, calculated as whole 
years between 1 January of the year of diagnosis and 31 December 2015, was 3 years (IQR 2-
5).  
The breakdown of surgical interventions undergone by the subset of patients with CD is 
given in Table 5.4. Each of the five cases with UC who underwent surgery had laparoscopic 
proctocolectomy with subsequent ileo-anal pouch formation. One patient with UC had a 
faecal transplant (not counted as a surgical intervention).  
 
5.3.9 EXTRA-INTESTINAL MANIFESTATIONS OF PAEDIATRIC IBD IN NEW 
ZEALAND 
Of the 212 patients with paediatric IBD in New Zealand on 30 June 2015, 40 (18.9%) of 
them had extra-intestinal manifestations of their disease. Of them, 32 had CD, three had UC 
and five had IBDU. The breakdown of extra-intestinal manifestations among this prevalent 
cohort of the PINZ study is given in Table 5.5. 
Rheumatological involvment included non-specific IBD-related arthralgia and arthritis. 
Dermatological involvement consisted of erythema nodosum as well as non-specific 
cutaneous rash thought related to IBD. Hepato-biliary involvement ranged from non-specific 
liver dysfunction to Type I autoimmune hepatitis and primary sclerosing cholangitis. 
Orofacial involvement was considerend in this study for cases with mouth ulcers, angular 
cheilitis and orofacial granulomatosis (with intestinal IBD); orofacial granulomatosis patients 
without intestinal inflammation were excluded from the PINZ study. One patient with 
paediatric IBD had arthralgia as well as anterior uveitis. 
 
5.3.10 INVESTIGATION MODALITIES UTILISED AT TIME OF DIAGNOSIS 
Of the 212 children with paediatric IBD in New Zealand on 30 June 2015, complete 
diagnostic information was available on 211 (99.5%) of them. Of these, all had colonoscopy 
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and 183 (86.7%) had an upper GI endoscopy at the time of diagnosis. One child was strongly 
suspected of having IBD at laparoscopy and this was confirmed at endoscopy shortly 
thereafter. Another patient was diagnosed and treated with steroids following sigmoidoscopy 
although diagnostic upper gastrointestinal endoscopy and colonoscopy was performed within 
six months of initial endoscopy. 
120 (56.6%) of the 212 cases had dedicated small-bowel imaging at the time of diagnosis, 
accepted as being within six months of a formal diagnosis. Eighty-five of these patients had 
magnetic resonance enterography, 29 had barium meal and follow-through, four had capsule 
endoscopy and one had a CT abdomen (as part of their work-up), which provided adequate 
visualisation of the small bowel. In one child, both magnetic resonance enterography and a 




















Table 5.4:  Surgery undergone by prevalent CD patients in New Zealand, 30/6/15 
Type of surgery 
 
Number of patients  
Ileocolic resection 4 
(Limited) right hemicolectomy 4 
Incision and drainage of peri-anal 
abscess(es) and/or laying open and/or 
placement of Seton for perianal fistula 
13 












* Excluding ileo-colic resection 
** Excluding ileo-colic resection and limited (right) hemicolectomy 
*** Each surgical intervention is counted just once for each patient; this patient also had a Seton placement accounting for the greater 
number of operations (27) than patients who required surgery (26) 
 
Table 5.5:  Extra-intestinal manifestations of paediatric IBD in New Zealand 
Organ system involved 
 
Type of IBD Number of patients affected 
Rheumatological CD 12 
Rheumatological IBDU 1 
Dermatological CD 5 
Hepato-biliary IBDU 4 
Hepato-biliary UC 3 
Hepato-biliary CD 5 
Orofacial IBDU 1 
Orofacial CD 13 
Ophthalmological CD 2 
  









5.4 KEY FINDINGS FROM CHAPTER 5 
1. The point prevalence of paediatric IBD, CD, UC and IBDU on 30 June 2015 were 
21.7, 16.5, 3.3 and 1.9 per 100 000 children, respectively. 
 
2. There was a striking disparity between the prevalence rates in the North and South 
Islands – the rates in the latter, in general, being considerably higher 
 
3. There was a non-significant male preponderance among the prevalent cohort for IBD 
(in general), CD and IBDU whereas UC demonstrated a non-significant female 
preponderance 
 
4. Nearly 10% of the prevalent cohort were ethnically Asian; the vast majority were 
European/Caucasian whereas Maori, Pacific Islanders and Middle Eastern children 
were also affected 
 
5. Greater than one in five of every child with IBD in New Zealand on 30 June 2015 had 
a positive family history of IBD 
 
6. Nearly 2/3 of those affected on 30 June 2015 had pan-colonic UC whereas over half 
among the CD cohort had ileo-colonic involvement; the overwhelming majority 
(90.1%) had an inflammatory phenotype of CD 
 
7. The rates of surgery for, and extra-intestinal manifestations of, paediatric IBD on 30 
June 2015 were 14.6% and 18.9% respectively. 
 
8. All cases of paediatric IBD were confirmed on colonoscopy (with nearly 87% having 
upper gastrointestinal endoscopy at the same time); over half of prevalent cases had 



















PROSPECTIVE INCIDENCE, DEMOGRAPHY AND DISEASE PHENOTYPE OF 














Incidence calculation provides a probability ratio of someone within the population being 
diagnosed with a particular disease. It can also suggest potential aetiological factors for a 
condition. When followed over time, the trend in incidence will guide current and future 
medical service provision for a particular community. Prospectively collected data negate all 
the weaknesses inherent in retrospective studies and is therefore the gold-standard in 
population-based epidemiological studies.  
The PINZ study sought to create New Zealand’s first nationwide paediatric IBD database. 
The aim of the database was to prospectively include every child diagnosed with the 
condition in this country in 2015, and into the future. With this resource, the incidence of 
paediatric IBD in New Zealand could be follwed over time. Also, the database was designed 
to collect information pertaining to drug and non-pharmacological therapy and surgical 
intervention, aside from anthropometric data. This would allow for, among other things, case-
control studies to be conducted in the future with regards to the efficacy and potential adverse 
effects of one treatment regimen over another.  
While all data that would be potentially useful for research purposes was not collected over 
the course of this Master’s project, the goal from the outset was to establish a sustainable 
study that could easily be taken over by another primary researcher once the author’s course 




6.2.1 CASE DEFINITION  
The definition of IBD is as described in section 2.4.1. Further to that, for inclusion into the 
part of the PINZ study described in this chapter, cases had to have been, under the age of 16 
years and formally diagnosed with IBD between 1 January 2015 and 31 December 2015 and, 





6.2.2 CASE RECRUITMENT AND DATA MANAGEMENT 
All paediatric patients with IBD in the South Island are currently enrolled in the database of 
the Crohns and Colitis Study referred to in section 3.2.2. During the year 2015, every person 
under the age of 16 years diagnosed with paediatric IBD in the South Island of New Zealand 
was also concurrently entered into the PINZ database following notification to the author.  
As discussed in section 5.2.2, information on patients in the North Island who met the 
inclusion criteria of this part of the PINZ study was obtained by liaising with the paediatric 
gastroenterology service at Starship Children’s Hospital in Auckland. During regular 
intervals over the course of the year, a list of patients under the age of 16 years newly 
diagnosed with IBD was forwarded to the author by the Head of Department of Paediatric 
Gastroenterology at Starship Children’s Hospital. This list would include patients resident in 
Auckland as well as other North Island locations who were seen by the srrvice at one of their 
outreach clinics. To ensure completeness of data collection, the other three paediatric 
gastroenterologists in Auckland were also individually e-mailed to confirm that the 
aforementioned list was complete and that all patients diagnosed by them, either in the public 
or private sector, were included. 
Data on patients cared for by adult gastroenterologists in the North Island were obtained 
through liaison with the NSZG, as discussed in section 5.2.2. 
Disease phenotypic and demographic features on each patient was then collected. Information 
on the South Island cohort was obtained as is described in sections 4.2.1 and 4.2.2. For 
patients living in the North Island, the same information was obtained from 3M. Ethnicity 
data on the latter subset were gathered from Concerto (another computerised patient 
information system of the ADHB) by an administrative assistant based in Auckland. 
Concerto lists only one ethnic group for each patient.  
 
6.2.3 POPULATION FIGURES 
To calculate the propective incidence of paediatric IBD in New Zealand for the year 2015, 
the estimated population figures for 0-15 year olds nationally as at 30 June 2015 was used as 
the denominator. The process by which these figues were attained is described in section 
5.2.3. and displayed in table 5.1.  
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6.2.4 STATISTICAL ANALYSIS 
All information was analysed descriptively. Comparisons between groups were made using 
the paired t-test. Numerical data are given as median, reported always with the relevant inter-
quartile range (IQR). Incidence rates are given with relevant 95% CI, calculated using the 
Byar approximation of Poisson distribution. Statistical significance was accepted if p<0.05. 
All statistical analysis was performed using GraphPad Prism version 6.00 (GraphPad 




6.3.1 PROSPECTIVE INCIDENCE OF PAEDIATRIC IBD IN NEW ZEALAND, 2015 
Between 1 January 2015 and 31 December 2015, 52 people under the age of 16 years were 
newly-diagnosed with IBD. Of them, 34 (65.4%) had CD, 11 (21.2%) had UC and the rest 
had IBDU. 
Incorporating the estimated population figure of 0-15 year olds in New Zealand (Table 5.1), 
the prospectively-calculated national incidence of paediatric IBD in 2015 was 5.3/100 000 
[95% CI 4.0-7.0] people under the age of 16 years. The incidence of CD, UC and IBDU 
respectively was 3.5/100 000 [2.4-4.9], 1.1/100 000 [0.6-2.0] and 0.7/100 000 [0.3-1.5] New 
Zealanders under the age of 16 years. 
 
6.3.2 PROSPECTIVE INCIDENCE OF PAEDIATRIC IBD BY REGION IN 2015 
A new diagnosis of paediatric IBD was made in 13 of the 16 regions of New Zealand in 
2015. Only three regions had five or more new cases during 2015 – Auckland, Canterbury 






Table 6.1: Distribution of incident cohort 2015 by regions in New Zealand 













 The “Others” rows consist of regions where the number of resident children with IBD was less than 5. 
These regions have been grouped together to ensure deidentification of the affected patients.  
 The North Island regions included in “Others” are Waikato, Hawke’s Bay, Taranaki, Manawatu-
Wanganui, Wellington and Bay of Plenty. The South Island regions are not given to preserve 
















6.3.3 GENDER DISTRIBUTION OF INCIDENT COHORT, 2015 
Of the 52 people newly diagnosed with paediatric-onset IBD in 2015, 29 were boys. This 
meant the male to female ratio of this incident cohort was 1.3:1. The male to female ratio of 
the CD cohort was 1.4:1 with 20 affected males. The same ratio for UC and IBDU was 1.2:1 
and 0.8:1 respectively, with six and four girls affected with each, respectively.  There was no 
significant difference between the genders for IBD nor any of its sub-types among the 
incident cohort (p=0.3).  
 
6.3.4 AGE DISTRIBUTION OF INCIDENT COHORT, 2015 
The median age of children and young people affected with IBD in the country on 31 
December 2015 was 12.9 years (10.3 – 14.7 years). The median age of patients with 
paediatric IBD by gender was 13.2 years (11.0-15.0 years) and 11.6 years (9.7-14.7 years), 
for males and females respectively. 
The median age of those affected by CD, UC and IBDU was 14.3 years (11.6-15.1 years), 
12.5 years (9.7-14.3 years) and 2.8 years (2.1-13.2 years), respectively. 
 
6.3.5 ETHNIC DISTRIBUTION OF INCIDENT COHORT, 2015 
Of the 52 children diagnosed with IBD in 2015, 45 (86.5%) had at least one parent, or 
identified, as ethnically European. Four (7.7%) had at least one parent, or identified, as Asian 
whereas two (3.8%) were of Middle Eastern heritage. One had child had one African parent 
whereas two (3.8%) identified as Maori.  
 
6.3.6 FAMILY HISTORY OF IBD AMONG INCIDENT COHORT, 2015 
One quarter of people under the age of 16 years diagnosed with IBD in 2015 had a 
documented positive family history of IBD. The degrees of relationship between the 13 cases 




6.3.7 PARIS CLASSIFICATION OF INCIDENT COHORT, 2015 
Cases with CD and UC were stratified according to the Paris classification system for 
paediatric IBD as discussed in section 2.4.2. 29 (85.3%) of the cases with CD were diagnosed 
aged 10 years or over. Ileo-colonic CD was the most common lower gastrointestinal tract 
location with 20 (58.8%)  of the included patients affected. 26 (76.5%) of CD patients had 
known upper gastrointestinal tract involvment whereas in two (5.9%) cases upper 
gastrointestinal endoscopy was not performed at diagnosis. Among the CD cohort, 5 (14.7%) 
had peri-anal involvement. With regards to disease phenotype, 32 (94.1%) had inflammatory 
CD whereas two (5.9%) had penetrating CD. 
Of the nine new cases of paediatric UC diagnosed in 2015 in new Zealand, five had proctitis 
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1            2            2            0               
0            0            0            0 
0            0            0            0 
0            0            0            0 
0            2            1            0  
0            0            0            0 
0            0            0            0 
1            0            1            0 
0            0            0            0 
0            0            0            0 
 
0             10          17         0 
0             0            0           0 
1             0            1           0 
0             0            0           0 
0             6            15         0 
0             1            0           0 
0             0            1           0 
1             1            2           0 
0             2            0           0 
0             3            2           0 
 
A1a: Diagnosed under 10 years of age   A1b: Diagnosed between ages 10-17 years   L1: ileal 
L2: colonic   L3: ileo-colonic   L4a: upper GI disease proximal to ligament of Trietz 







6.3.8 SURGERY FOR INCIDENT COHORT, 2015 
One child diagnosed with peri-anal CD in 2015 required a fistulotomy. That was the only 
surgery undergone by anyone under 16 years of age newly-diagnosed with IBD in New 
Zealand in 2015. 
 
6.3.9 EXTRA-INTESTINAL MANIFESTATIONS OF INCIDENT COHORT, 2015 
Of the 52 patients newly-diagnosed with paediatric IBD in New Zealand in 2015, eight 
(15.4%) had extra-intestinal manifestations of their disease. All but one of them had CD – the 
only exception being a case with IBDU. The breakdown of extra-intestinal manifestations 
among this incident cohort of the PINZ study is given in Table 6.3. 
Rheumatological involvment consisted of non-specific IBD-related arthritis. Dermatological 
involvement consisted of erythema nodosum. Hepato-biliary involvement included 
autoimmune hepatitis and primary sclerosing cholangitis. Orofacial involvement was 
considerend in this study for cases with mouth ulcers, angular cheilitis and orofacial 
granulomatosis (with intestinal IBD); orofacial granulomatosis patients without intestinal 
inflammation were excluded from the PINZ study. One patient within the incident cohort had 
oral ulcers and erythema nodosum. 
 
6.3.10 INVESTIGATION MODALITIES UTILISED AT TIME OF DIAGNOSIS FOR 
INCIDENT COHORT, 2015 
All 52 patients newly-diagnsoed with paediatric IBD in New Zealand in 2015 had a 
colonoscopy as part of their diagnostic work-up. All but four (7.7%) of those patients had an 
upper gastrointestinal endoscopy at the same time. As of 31 December 2015, 32 (61.5%) of 
the incident cohort had had dedicated small bowel imaging as part of their work-up within six 
months of diagnosis. Of these, 27 had MRE whereas four had a barium meal and follow-
through. One person had a CT abdo for the specific purpose of visualing their small bowel as 
she could not tolerate an MRE. It is worth noting that not all among the incident cohort were 




 Table 6.3:  Relationship of family members to cases with positive family history of  IBD 
Degree(s) of relationship 
 
Number of cases  
First 8 
Second 2 
Greater than fourth 2 
Not specified 1 
 
 For cases who have more than one affected family member, their degree of relationship with the most 
closely affected member is documented 
 
Table 6.4:  Extra-intestinal manifestations of paediatric IBD in New Zealand 
Organ system involved 
 
Type of IBD Number of patients affected 
Rheumatological CD 2 
Dermatological CD 1 
Hepato-biliary IBDU 1 
Hepato-biliary CD 2 
Orofacial CD 3 
  
















6.4 KEY FINDINGS FROM CHAPTER 6 
1. The prospectively-calculated incidence of paediatric IBD, CD, UC and IBDU in New 
Zealand in 2015 were 5.3, 3.5, 1.1 and 0.7 per 100 000 children, respectively. 
 
2. The region with the highest number of new cases in 2015 was Canterbury – with 15. 
 
3. Most ethnic groups present in New Zealand were represented among the incident 
cohort in 2015; only European/Caucasian children were over-represented 
 
4. One quarter of children diagnosed with IBD in New Zealand in 2015 had a family 
history of IBD 
 
5. Nearly 60% of the new diagnoses in 2015 had ileo-colonic CD whereas greater than 
three quarters had upper gastrointestinal involvement; the vast majority (94.1%) had 
an inflammatory phenotype of CD; the majority of UC diagnoses in 2015 had proctitis 
 
6. The rates of surgery for, and extra-intestinal manifestations of, paediatric IBD in 2015 
were 1.9% and 15.4% respectively. 
 
7. All cases of paediatric IBD were confirmed on colonoscopy (with greater than 90% 
having upper gastrointestinal endoscopy at the same time); over 60% of incident cases 









































The PINZ study was and continues to be well-supported by all paediatric gastroenterologists 
working in New Zealand. As a direct result of this cooperation, the completeness of data 
contained within the PINZ database is of a high-level. This has already borne fruit as 
demonstrated by the results discussed in the preceding chapters of this thesis. It is further 
hoped that the set-up of the PINZ study is such that a seamless transition will occur enabling 
the next primary researcher to continue to prospectively enter all young people under 16 
years of age diagnosed with IBD in New Zealand. With this, the PINZ database will be a 
treasure trove of national, population-based information on paediatric IBD, which will 
hopefully spawn multiple studies for years to come. 
 
7.2 CHAPTER 3 
The annual incidence rate of paediatric IBD in Canterbury has more than quadrupled in 20 
years. In 1996, the rate was 2.88/100 000 [0.58-8.40] children whereas in 2015, the rate had 
increased to 13.06/100 000 [7.31-21.56] children. The highest annual incidence rate was 
observed in 2014 – 13.17/100 000 [7.37-21.73] children. Over the 20-year study period, the 
mean annual incidence of paediatric IBD in Canterbury was 7.18/100 000 [5.55-8.81]. Over 
the last ten years of the study period (2006-2015) the mean annual incidence was 9.73/100 
000 [7.97-11.48] whereas for the last five years of the study period (2011-2015) the mean 
annual incidence was 10.54/100 000 (7.25-13.84). 
When the mean annual incidence rates over five year time-frames were analysed, a 
statistically-significant upward trend was noted (Figure 3.3). There was also a significant 
upward trend in the difference between the mean annual incidence of paediatric IBD in 
Canterbury between 1996-2000 and 2011-2015 (Figure 3.3). Linear regression analysis 
revealed a statistically-significant increase in the annual incidence rates over the 20-year 
study period (Figure 3.4). 
The descriptive epidemiology of paediatric IBD is reviewed in detail in Chapter 1. The 
incidence rates observed in Canterbury are some of the highest documented anywhere in the 
world. Indeed, the incidence rates noted in 2014 and 2015 are the highest yet published.
15
 
Although higher rates were observed in southwestern Ontario,
68
 that study included children 
older than the age cut-off for the PINZ study.  
89 
 
The design of the study described in Chapter 3 was retrospective in nature (except for 2015 
data which were collected prospectively). While every effort was made to ensure the 
completeness of information gathered, it is likely that some cases would have been 
overlooked. Also in some of the cases that were identified, certain details relevant to the 
study were unavailable. These factors notwithstanding, information on paediatric IBD 
diagnoses in Canterbury since 2009 have been collected in a prospective fashion. Also more 
than one source was searched during the current study, which minimises the likelihood of 
eligible cases being missed. These included patients seen in both the public and private 
sectors.  
Also the nature of healthcare practices in Canterbury makes the likelihood of IBD care for 
local children being sought, exclusively, in another centre almost non-existent. The 
centralisation of paediatric gastroenterology in the region as well as the co-operation between 
paediatric and adult medicine in Canterbury, and among the CDHB and SCDHB, ensured 
that this study was well-supported clinically and truly population-based.  
There are a few factors which could explain the increased incidence of paediatric IBD in 
Canterbury. The appointment of a full-time paediatric gastroenterologist to the region in 2009 
may well account for an increase in the number of referrals to tertiary paediatric care. It is 
conceivable that a greater proportion of patients are being diagnosed at a younger age as 
opposed to experiencing a lag to eventual diagnosis by an adult gastroenterologist. Also the 
2004 study, which reported for the first-time the significant burden of IBD among the 
Canterbury population, will have invariably increased awareness of these conditions amongst 
medical professionals and lay-people alike. The impact of the Canterbury earthquakes on the 
physical and emotional health of Cantabrians as well as on the composition of its citizenry 
may also be contributory.  
It is very likely however that the increased incidence of paediatric IBD in Canterbury does 
represent a true increase in the occurrence of this condition. This is particularly true when the 
results of other population-based epidemiological studies also, almost universally, point to an 






7.3 CHAPTER 4 
Arguably the most striking finding among the results discussed in Chapter 4 is the marked 
preponderance of CD compared to UC (and IBDU) among the cohort of children diagnosed 
with IBD in Canterbury between 1996 and 2015. The ratio of CD to UC in this study, 8.4:1, 
is the highest reported anywhere in the literature. This trend is in keeping with a previous 
study,
54
 which demonstrated an exponential increase in the incidence of CD in Canterbury 
compared to a relatively stable incidence of UC.   
There were more males than females affected by paediatric CD, whereas the reverse was true 
for paediatric UC, among the study cohort. These differences, while not significant, are in 
keeping with gender predisposition data from other studies.
43
 While the vast majority of the 
study cohort was ethnically European, there were cases of IBD affecting Asian, Maori and 
Pacific Islander Cantabrians. Indeed the cases of Pacific Islanders in the PINZ study may be 
the first ever description of CD affecting that particular ethnic group. In the only previous 
study focussing exclusively on paediatric IBD in New Zealand,
55
 no Maori or Pacific Islander 




With regards to disease phenotype, the findings arising from the study described in Chapter 4 
are largely in keeping with evidence available in the literature.
7, 20, 21, 43
 Specifically, the 
predominance of ileo-colonic CD and pan-colonic UC , replicated in this study, typifies the 
more extensive organic involvement that is characteristic of paediatric-onset IBD. The 
percentage of CD patients with peri-anal involvement in the current study is slightly lower 
than a previous population-based study conducted in Canterbury 
85
, and including IBD 
patients of all ages, which suggested a 26% rate of peri-anal involvment in those IBD patients 
with CD. 
The main weakness of the results described in Chapter 4 is the small gaps in information. For 
example, in fourteen and eighteen cases respectively, ethnicity and diagnostic modalities data 
were unavailable. While every reasonable effort was made to rectify these deficiencies in 
knowledge, case notes were not obtainable in all instances when they would have been 
helpful (in some cases because of the effects of the Canterbury earthquakes). Further to that, 
ethnicity data in Chapters 4-6 were obtained from patient management systems. While a 
convenient method, it is not without fault. Often times, only one ethnicity is listed for every 
patient (even in cases when more than one may apply). Indeed, presumption on the part of 
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clerical staff sometimes means that ethnicity data are assumed to be known rather than 
explicitly confirmed with a patient or parent/guardian, something that may have led to 
misclassification of cases’ ethnicities.  
 
7.4 CHAPTER 5 
The national prevalence of paediatric IBD in New Zealand on 30 June 2015 was 21.7/100 
000 [18.9-24.8]. In a systematic review conducted by Cameron et al,
86
 and published in 
abstract form in 2014, prevalence rates for paediatric IBD are listed as being between 6.0-
30.0/100 000 children. The abstract decried the lack of any true population-based studies and 
concluded that paediatric IBD prevalence was highest in North America and Europe. 
Results from the PINZ study described in Chapter 5 may well represent the first, population-
based, national prevalence rate of paediatric IBD ever published. These results clearly show 
that the prevalence of paediatric IBD in New Zealand is significant and comparable to some 
of the highest rates in other places in the world. 
By virtue of engaging every paediatric gastroenterologist currently practising in New 
Zealand, the PINZ study was able to ensure full co-operation of the two centres in New 
Zealand that provide specialist paediatric gastroenterological care. This ensured a through 
and robust search for every patient with IBD meeting criteria to be included in this study. 
Further to that, in centres where older children were sometimes cared for in adult services 
(either in the public or private sectors) key adult gastroenterologists were contacted, and 
obliged in every instance. Though an unknown number of patients with paediatric IBD who 
met inclusion criteria may not have been identified by the PINZ study, the likelihood is that 
that number is small.  
Another remarkable finding from Chapter 5, is the north-south discrepancy between 
prevalence rates of paediatric IBD in New Zealand. The prevalence rates in five out of the 
seven regions in the South Island are higher than the top-end of the range given in the 
aforementioned systematic review.
86
 The PINZ study is based in Canterbury and this may 
account for a degree of under-estimation insofar as case identication in the North Island. But 
because of the robust methodology employed, and the close co-operation of the North Island 
gastroenterology community notwithstanding, this difference is likely to be significant. 
Evidence from Europe and North America has shown a similar North-South gradient but in 
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reverse - with geographical locations at higher latitude tending to have higher IBD burden.
22, 
87-89
 Findings arising from the PINZ study may be the first in the world to show higher 
prevalence rates in the southern part of a country compared with its northern counterpart. 
Rather than contradicting existing results, findings from the current study likely reiterate the 
important association between vitamin D (as a surrogate of sunlight exposure) and IBD, as 
discussed briefly in Chapter 1.  
The ratio of CD:UC:IBDU among the prevalent cohort was approximately 15:3:2. This 
suggests a significant predominance of CD over UC and IBDU nationally, in keeping with 
the Canterbury data described in Chapter 4. There was also a male preponderance overall as 
well as within all sub-groups except for UC. The predominance of ileo-colonic CD and pan-
colonic UC was, again, in keeping with paediatric IBD trends elsewhere described. 
 
7.5 CHAPTER 6 
The results described in Chapter 6 are from the pilot arm of the PINZ study, which sought to 
prospectively collect information on every new paediatric IBD diagnosis made in New 
Zealand in 2015. By enlisting the co-operation of every paediatric gastroenterologist, and of 
key adult gastroenterologists in different centres in New Zealand, the PINZ study can lay 
claim to having a comprehensive and robust methodology. 
In 2015 the incidence rates for paediatric IBD, CD, and UC in New Zealand were 5.3, 3.5, 
and 1.1 per 100 000 children, respectively. These figures are considerably higher than those 
obtained from the national survey conducted over a decade earlier -  2.9, 1.9 and 0.5/100 000 
children for IBD, CD and UC, respectively.
55
 Taken together, these show a near doubling of 
the incidence of paediatric IBD and its sub-types within a 12-year time frame. The nation-
wide incidence rate obtained in 2015 by the PINZ study is comparable with those reported in 




 reporting higher, national 
incidence rates. 
The proportion of children with a positive family history of IBD was higher in the PINZ 
study than that reported in the survey published in 2008.
55
 In the current study one quarter of 
newly-diagnosed children in 2015 had at least one family member who also had IBD – in 





 only 10% of incident cases had a first or second-degree family member 
who also had IBD. 
It is conceivable that, particularly in the smaller centres in New Zealand, some cases of 
paediatric IBD may be managed locally with no specialist (paediatric) gastroenterology input. 
The design of the PINZ study means that cases such as those, diagnosed in 2015 and beyond 
will not be identified. Consensus among senior colleagues within gastroenterology nationally 
is that that number is likely to be small. However taking into account that possible oversight, 
the incidence rates here given might in fact be an under-estimate of the actual rates.  
In a similar vein, the New Zealand incidence rates quoted in the 2008 publication
55
 may well 
have been an under-representation of the actual figures particularly as that study was 
conducted in survey form - necessitating voluntary reporting on the part of the 
overseeing/diagnosing physician. However, it is worth noting that the aforementioned study 
reported admirably high response rates which would have minimised the likelihood of missed 
cases. Therefore, assuming that the spread of missed cases was even between the previous 
and current studies, the increase in paediatric IBD incidence in New Zealand is a real 
phenomenon. 
 
7.6 FUTURE DIRECTIONS OF PINZ STUDY 
From 2016 onwards, the PINZ database is going to be managed full-time by a dedicated 
assistant research fellow with oversight and continued involvement of the author and 
supervisors of this thesis. Therefore, the inclusion of new cases of paediatric IBD diagnosed 
anywhere in the country into the PINZ database is set to continue. This will allow for the 
trend of incidence rates nationally, over time, to be evaluated in a prospective manner and 
with uniform methodology. 
Also, the set-up of the PINZ database allows for the assessment of anthropometric parameters 
and the success (and side-effects) of different therapeutic interventions such as EEN and 
immunosuppresive therapies.  
In the long-run it is hoped that this population-based disease-specific database will prove an 
invaluable resource for conducting epidemiological and related research into a condition 
which is clearly of great significance to the New Zealand population.  
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7.7 NOVEL FINDINGS ARISING FROM THE PINZ STUDY 
1. The incidence of paediatric IBD in Canterbury has more than quadrupled between 
1996 and 2015 
 
2. The ratio of paediatric CD to UC in Canterbury between 1996 and 2015 is the highest 
published 
 
3. This is the first study to acknowledge and include CD patients of Pacific Island 
heritage 
 
4. The point prevalence of paediatric IBD, CD, UC and IBDU in New Zealand on 30 
June 2015 was 21.7, 16.5, 3.3 and 1.9 per 100 000 children, respectively – these may 
represent the first-ever national, population-based prevalence rates of paediatric IBD 
 
5. The existence of a north-south gradient in New Zealand, with higher prevalence of 
paediatric IBD in the lower lattitudes, is described here for the first time 
 
6. The prospectively-calculated incidence of paediatric IBD, CD, UC and IBDU in 2015 
in New Zealand was 5.3, 3.5, 1.1 and 0.7 per 100 000 children, respectively – a near-



































Canterbury is located in the South Island of New Zealand. It has the second largest 
population out of the 16 regions in the country - home to 12.7% of New Zealand’s 
population.
90
 Canterbury’s ethnic make-up is relatively homogenous compared to the rest of 
the country, with a higher percentage of European or Caucasian peoples than that in New 
Zealand as a whole.
90
 Christchurch City is the main urban centre in Canterbury and is home 
to nearly two-thirds of the region’s population.
91
 Ashburton and Timaru are two other 
independent urban communities within the region with other areas becoming increasingly 
rural the further away from these centres they are geographically situated. The median 
personal income in Canterbury in 2013 was NZD30 100, higher than the national median.
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Christchurch was severely affected by a series of earthquakes in 2010 and 2011. 
 
A.1.2 GEOGRAPHIC MAKE-UP 
Canterbury is New Zealand’s largest region in terms of land mass. The region is made up of 
10 separate districits namely, Kaikoura, Hurunui, Selwyn, Waimakariri, Christchurch City, 
Ashburton, Timaru, Mackenzie, Waitaki (which is partly of the Otago region) and Waimate.
93
 
The numerous cities and towns within Canterbury are concentrated on the east coast of the 
South Island.  
 
A.1.3 DEMOGRAPHIC MAKE-UP 
Since 2011, when Christchurch experienced negative population growth (and the surrounding 
districts of Waimakariri and Selwyn experienced the reverse), Christchurch’s and indeed, 
Canterbury’s, population has continued to grow. As of the last national census conducted in 
2013, the population of Canterbury was 539 436 people.
90
 As a whole, Canterbury has an 
ageing population, with its median age (39.9 years) and percentage of people aged 65 years 
and older higher (15.5%) and its percentage of people aged under 15 years (18.7%) lower, 
than the national figures.  86.9% of people residing in Canterbury are ethnically European, 
higher than the national figure of 74%. The other main ethnic groups in Canterbury are the 




A.2  Map of Canterbury  
Source: Environment Canterbury, accessed at http://ecan.govt.nz/publications/General/map-




A.3  Distribution of urban and rural areas within the Canterbury region 
 
Source: Statistics New Zealand, accessed at 
http://www.stats.govt.nz/~/media/Statistics/browse-categories/maps-and-









A.4 PROFILE OF NEW ZEALAND 
Situated in the South Pacific, with a land mass similar to that of the United Kingdom, New 
Zealand is made up of the North Island and the South Island.
94
 As of 30 June 2015, New 
Zealand’s estimated resident population was 4.6 million.
94
 The vast majority of New 
Zealanders identify as European (74.6%) whereas Maori (15.6%), Asian (12.2%) and Pacific 
peoples (7.8%) are the other significant ethnic groups within the country.
94
 
New Zealand has an aging population (see Figure 4.2).
95
 Its median age in 2014 was 37.5 
years and this is projected to rise to 40.9 years in 2034.
94
  New Zealand has a mixed economy 
with a significant service sector, complemented by a productive agricultural and related 
manufacturing industry.
94




















A.5 Population distribution in New Zealand 
 
Source: Statistics New Zealand, accessed at 
http://www.stats.govt.nz/browse_for_stats/snapshots-of-nz/nz-in-profile-
2015/population.aspx on 29/9/2015 
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A.6 Ethical approval from HDEC for PINZ study (amendment to existing approval for 
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